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Abstract 
 
 
Background 
The abuse of alcohol and illegal drugs is an important and clinically challenging 
aspect of the management of patients in psychiatric hospitals. Many of these patients 
have comorbid mental illness, which can complicate the treatment course. The 
patients might end up being sent between addiction units, psychiatric wards, and 
somatic hospitals. In Norway, some of these patients are admitted and treated 
involuntarily in hospitals, pursuant to either the Mental Health Care Act or the Social 
Services Act. The ethical questions surrounding involuntary admission are a growing 
concern, and the subject has not been studied sufficiently. Therefore, this thesis 
focuses on substance use disorders (SUDs) and involuntary admission.  
 
Study aims 
The overall objective of this thesis is to investigate the relationship between 
substance use patterns and involuntary admission to hospitals in different settings 
pursuant to two different laws. First, we describe and compare involuntarily admitted 
(IA) and voluntarily admitted (VA) patients with SUDs according to sociodemographic 
characteristics. Second, we examine whether typical patterns of diagnostic 
comorbidity exist in association with involuntary admission. We also investigate 
factors associated with the involuntary admission of patients with SUD. 
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Materials and methods 
Study 1 was a cross-sectional, national multicenter study of SUD in 3,506 patients 
admitted to adult acute psychiatric wards. Study 2 was a regional, comprehensive 2-
year follow-up study carried out in a select population of patients with first episode 
psychosis (FEP). Patients in Studies 1 and 2 were admitted to psychiatric wards 
pursuant to the Mental Health Care Act. Study 3 was a cross-sectional, regional 
study comparing patients with SUD who were IA or VA to addiction treatment centers 
pursuant to the Social Services Act. The Diagnostic and Statistical Manual of Mental 
Disorders (DSM)-IV, the International Classification of Diseases (ICD)-10, the Global 
Assessment of Functioning (GAF) instrument, Clinician Rating Scale (Alcohol and 
Drug Use Scale), Symptom Checklist-90-R (SCL-90-R), and Addiction Severity Index 
(ASI) were used. 
 
Results 
In all three studies, the majority of patients were male, relatively young between 20-
30 years of age, and relatively few were living with a partner. The number of patients 
with comorbid SUD and mental health disorder were relatively high. In Study 1, we 
found that approximately one-third of the patients admitted to acute psychiatric wards 
had a comorbid disorder, but fewer FEP patients had comorbid SUD (Study 2). The 
largest difference between IA and VA patients was found among FEP patients, with 
comorbidity being much more frequent among IA patients. SUD among patients with 
FEP was significantly associated with involuntary admission. Among patients IA and 
VA to addiction treatment centers (Study 3), we found that comorbidity was frequent 
in both groups. Demographic characteristics (i.e., gender, sources of income) and the 
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severity of drug use (i.e., injecting drugs, overdoses) predicted involuntary admission 
to an institution, not the presence of mental disorders or SUD. 
 
Discussion and conclusion 
Comorbid SUD and mental disorders renders treatment more difficult and presents a 
major challenge to health service providers, indicating the need to diagnose and treat 
these patients within a highly competent system. Therefore, clinical routines that 
better identify SUD among patients receiving care for mental health disorders should 
be given higher priority, as many of the patients would likely benefit from integrated 
specialist services including mental health, somatic health, and SUD treatment.  
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Norwegian summary (norsk sammendrag) 
 
 
Bakgrunn 
Misbruk av alkohol og illegale rusmidler er et viktig og klinisk utfordrende problem i 
behandlingen av pasienter i psykiatriske sykehus. Mange av disse pasientene har en 
komorbid psykiatrisk sykdom. Dette kan komplisere behandlingsforløpet og 
pasientene risikerer ofte å bli sendt mellom ulike institusjoner, som rusbehandlings 
enheter, psykiatriske og somatiske sykehus. I Norge blir noen av disse pasientene 
tvangsinnlagt på sykehus enten etter Lov om psykisk helsevern eller etter Lov om 
sosiale tjenester. Det er en økende bekymring rundt de etiske spørsmålene knyttet til 
bruk av tvang i psykiatrien, men problemet har ikke blitt tilstrekkelig undersøkt 
tidligere i denne pasientgruppen. På bakgrunn av dette, fokuserer denne 
avhandlingen på tvangsinnleggelser av pasienter med ruslidelser.  
 
Forskningsmål 
Hovedmålet med avhandlingen er å undersøke sammenhengen mellom 
rusmiddelbruk og tvangsinnleggelser i ulike institusjoner etter de to nevnte lover. 
Først har vi beskrevet og sammenlignet tvangsinnlagte og frivillig innlagte pasienter 
med ruslidelser i forhold til sosialdemografiske karakteristika. Deretter undersøkte vi 
om det var typiske komorbiditetstrekk mellom ruslidelse og psykiske lidelser knyttet til 
tvangsinnleggelse. Vi har også undersøkt hvilke faktorer som var assosiert med 
tvangsinnleggelse av pasienter med ruslidelse. 
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Material og metode 
Studie 1 er en nasjonal, multisenter tverrsnittsstudie av ruslidelser blant 3,506 
pasienter innlagte i akuttpsykiatriske avdelinger. Studie 2 er en regional, 2-års 
oppfølgingsstudie utført i en utvalgt populasjon av pasienter med første episode av 
psykose (FEP). Pasientene i Studie 1 og 2 ble innlagt i psykiatriske avdelinger etter 
Lov om psykisk helsevern. Studie 3 er en regional tverrsnittsstudie som 
sammenligner tvangs- og frivillig innlagte pasienter med ruslidelse etter Lov om 
sosiale tjenester i tre norske rusbehandlingsinstitusjoner. 
 Vi brukte diagnostiske manualer som DSM-IV for psykiske lidelser og ICD-10 for 
internasjonal klassifisering av sykdommer, Symptom Checklist-90-R (SCL-90-R) 
instrument og Global Assessment of Functioning (GAF) instrument, dessuten 
Clinician Rating Scale og den europeiske Addiction Severity Index (EuropASI) for 
gradering av alkohol- og narkotikabruk.  
 
Resultat  
I alle tre studiene var flertallet av pasientene unge menn i alderen 20-30 år, og 
relativt få var gifte eller samboere. Antall pasienter med komorbid ruslidelse og 
mental lidelse var forholdsvis høyt. I Studie 1 fant vi at omtrent en tredjedel av 
pasientene som ble innlagt i akuttpsykiatriske avdelinger hadde en komorbid 
ruslidelse. Det var færre med komorbid ruslidelse blant FEP pasientene (Studie 2). 
Den største forskjellen mellom tvangs- og frivillig innlagte pasienter fant vi blant FEP 
pasientene. Komorbiditet var mye hyppigere blant de tvangsinnlagte pasientene og 
ruslidelse hos pasienter med FEP var signifikant assosiert med tvangsinnleggelse. 
Blant tvangs- og frivillig innlagte pasienter til rusbehandling (studie 3) fant vi høy 
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komorbiditet i begge gruppene (60% vs. 75%). Demografiske karakteristika som 
kjønn (kvinner, mottakere av trygdeytelser, tung rusbelastning og svekket fysisk 
helse var sterkere assosiert med tvangsinnleggelser enn psykiatriske diagnoser. 
Mens menn dominerte blant tvangsinnlagte pasienter med ruslidelser etter Lov om 
psykisk helsevern, var det relativt flere unge kvinner innlagt etter Lov om sosiale 
tjenester.  
 
Diskusjon og konklusjon 
Komorbiditet med samtidig rus og psykisk lidelse vanskeliggjør behandlingen. 
Komorbiditet representerer derfor en stor utfordring for helsevesenet. Det er behov 
for å diagnostisere og behandle disse pasientene i et system med høy faglig 
kompetanse. Kliniske rutiner for å identifisere ruslidelse blant pasienter som mottar 
psykiske helsetjenester bør derfor gis høyere prioritet fordi mange av pasientene vil 
ha nytte av integrerte spesialisthelsetjenester innen mental helse, somatisk helse og 
tverrfaglig, spesialisert rusbehandling. 
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Preface 
 
When I was working as a nurse in infectious disease wards, I met patients with SUDs 
and was troubled by the fact that some of them left the ward even though they had a 
deadly disease. I often wondered what we could do to help these patients. One 
moment the patients wanted help, but the next moment persuading them to stay in 
the hospital was impossible, even when they were being treated for life-threatening 
infections, such as endocarditis. I felt powerless when I saw these patients leave the 
hospital looking for the next shot of heroin. I wished there was a miracle cure that 
could help them out of the captivity of abuse and motivate them to take care of their 
own physical and mental health. Involuntary admission of these patients was never 
considered as an option in that clinical environment.  
My interest in this research topic started when I was a member of the hospital 
research committee and reading applications for research funding. Øistein 
Kristensen, a fellow member of the research committee, introduced me to the topic of 
involuntary admission. First, I was doubtful that this was a good idea. Could 
involuntary admission really help these patients, or was it just used as an excuse to 
“store” unwanted people and to remove an unpleasant sight from the public? The 
answers to these questions were not easily available, as no evaluations of the 
treatment outcomes in Norway were available. 
When I first started this research project, the goal was to investigate factors related to 
the involuntary admission of patients to addiction wards pursuant to the Social 
Services Act. The original project plan was a longitudinal study with a 6-month follow-
up to evaluate long-term treatment outcomes. The law has been in limited use; 
therefore, data collection took longer than initially anticipated. As relatively few 
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patients were admitted to the wards, we were curious if the patients with comorbid 
substance use disorder and psychiatric disorder might be somewhere else. Could 
they have been involuntarily admitted to mental health institutions instead of 
addiction treatment centers? We were privileged to get access to two other data 
collections, resulting in papers I and II, with which we could explore this phenomenon 
in different patient populations while collecting data for the original project. Data 
collection for the original protocol (paper III) was completed in April 2012, including 
follow-up data. However, in this thesis, only data from the baseline data collection 
were included in paper III. The information on long-term outcomes from this study will 
be presented in forthcoming publications. 
As far as we know, this is the first Norwegian thesis in psychiatry investigating both 
involuntary admittance and substance use disorders. Previous research has focused 
only on admittance to mental health care or comorbid substance abuse and mental 
illness, but there is a lack of knowledge regarding the combination of the two topics, 
substance use disorders and involuntary admissions.  
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1. Introduction 
 
In this thesis, substance-using patients involuntarily admitted (IA) to hospitals were 
investigated in different settings. First, we investigated patients admitted to acute 
psychiatric wards according to substance use disorder (SUD) and the legal basis for 
admission. In the second study, IA patients with first-episode psychosis (FEP) and 
SUD were examined. In the third study, we investigated SUDs among patients IA to 
addiction treatment units. 
In these studies, two different diagnostic systems were used to define the patients’ 
mental disorders and substance use patterns: the Statistical Manual of Mental 
Disorders (DSM) by the American Psychiatric Association (2) and the International 
Classification of Diseases (ICD) by the World Health Organization (4). In Norway, the 
ICD is mandatory in clinical use, whereas the DSM is often used in scientific 
research. In these studies, the term substance abuse was used in papers I-II. In 
paper III and this thesis SUD has been used. The latter includes harmful use, 
substance abuse and substance dependence (2). In DSM-IV, the conditions are 
formally diagnosed as one or the other, but the new DSM-V has proposed to combine 
the two into a single condition, SUD (7). 
According to DSM-IV, substance abuse is a pattern of substance use leading to 
significantly impaired functioning. One of the following must be present within a 12-
month period:  
 Recurrent use resulting in a failure to fulfill major obligations at work, school, 
or home. 
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 Recurrent use in situations that are physically hazardous (e.g., driving while 
intoxicated). 
 Legal problems resulting from recurrent use. 
 Continued use despite significant social or interpersonal problems caused by 
substance use.  
The symptoms do not meet the criteria for substance dependence, which includes 
the substance use history. Three or more of the following seven requisites should 
have been met during the same 12-months period 
 
 Increase in tolerance (more of the drug is needed to achieve the same effect). 
 Withdrawal symptoms. 
 The substance is often taken in larger amounts or over a longer period than 
was intended. 
 There is a persistent desire or unsuccessful efforts to cut down or control 
substance use. 
 A great deal of time is spent in activities necessary to obtain the substance. 
 Important social, occupational, or recreational activities are given up or 
reduced. 
 The substance use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been caused 
or exacerbated by the substance. 
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ICD-10 (4) section F10-F19 “Mental and behavioral disorders due to psychoactive 
substance use” contains a variety of disorders of different severity and clinical form, 
all including the use of one or more psychoactive substances, which may or may not 
have been medically prescribed. The substances specified are alcohol, opioids, 
cannabinoids, sedatives or hypnotics, cocaine, other stimulants including caffeine, 
hallucinogens, tobacco, and volatile solvents. The clinical states that can occur 
include acute intoxication, harmful use, dependence syndrome, withdrawal syndrome 
(state), withdrawal state with delirium, psychotic disorder, late-onset psychotic 
disorder, and amnesic syndrome (8). A definite diagnosis of dependence is usually 
made if three or more of the following were present together at some time during the 
previous year: 
 A strong desire or sense of compulsion to take the substance. 
 Difficulties controlling substance-taking behavior in terms of its onset, 
termination, or level of use. 
 A physiological withdrawal state when substance use has ceased or been 
reduced, as evidenced by the characteristic withdrawal syndrome for the 
substance or use of the same (or closely related) substance with the intention 
of relieving or avoiding withdrawal symptoms. 
 Evidence of tolerance, such as increased doses of the psychoactive 
substance being required in order to achieve effects originally produced by 
lower doses; clear examples of this are found in alcohol- and opiate-
dependent individuals who may take daily doses sufficient to incapacitate or 
kill non-tolerant users. 
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 Progressive neglect of alternative pleasures or interests because of 
psychoactive substance use, increased amount of time is needed to obtain or 
take the substance or to recover from its effects. 
 Persisting with substance use despite clear evidence of overtly harmful 
consequences, such as harm to the liver through excessive drinking, 
depressive mood states consequent to periods of heavy substance use, or 
drug-related impairment of cognitive functioning; efforts should be made to 
determine that the user is actually, or could be expected to be, aware of the 
nature and extent of the harm. 
 
1.1 Substance use disorders and mental illness 
An SUD with alcohol or illegal drugs is an important and clinically challenging aspect 
of the management of patients in psychiatric hospitals. Many of these patients have a 
comorbid mental illness (9-11), and deciding which problem came first could be 
difficult (12). Drug-using patients are reported to have a higher risk of violent behavior 
(13) and to be hospitalized, homeless, or in jail (14). Some studies have revealed that 
these patients tend to have a higher risk of suicide or sudden death (15-17), and 
poorer treatment compliance (18). These factors can complicate the treatment course 
and the patients often end up being sent between addiction units, psychiatric wards, 
and somatic hospitals. Substance abuse has been known for centuries (19, 20). 
Today, substance abuse is commonly seen as a disease, as well as a social problem 
and problem of public order and security, or a combination of these. In this study, 
SUD refers to substance abuse and substance dependence, including both alcohol 
and illicit drugs.  
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1.2 Autonomy 
In psychiatry and social services, caregivers primarily try to treat patients voluntarily 
(21, 22) but sometimes feel required to restrict freedom and use involuntary 
treatment. The ethical questions related to the use of involuntary treatment are a 
growing concern, particularly when it is used pursuant to the Mental Health Care Act. 
Freedom of choice and patient rights are important ideals in today's Western society, 
even though compulsory practices are still relatively common in mental health care. 
Involuntary treatment is ethically problematic because it involves acting against an 
individual’s autonomy. Autonomy is the capacity to make an informed, voluntary 
decision. The ability of the individual to make his/her own choices has been 
perceived as the basic foundation of social freedom and moral responsibility (23). 
The opposite is paternalism, which involves acting against other people’s choices 
and will for their own benefit or to prevent them harm (24).  
 
1.2.1  Autonomy of SUD patients 
Standard definitions of SUD cite loss of control, powerlessness, and unmanageability 
(25). SUD patients who are truly addicted to alcohol or drugs may not have the full 
capacity to be self-determining or autonomous at all times (26). Therefore, 
involuntary treatment may be justified, even for only a short period, if treatment can 
remove the powerlessness and loss of control caused by the compulsive drug-taking 
habits consequent to SUD (26). SUD patients with comorbid mental illnesses and 
disabilities are not always incompetent in terms of autonomy. Indeed, to function as a 
drug-dependent person, the individual must be able to reason, remember complex 
information, set goals, and be orientated to time, place, and personal identity, but 
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competency by itself is not sufficient for autonomy. Being competent is a part of 
autonomy, but autonomy also requires freedom from coercion (27). In 2008, Arthur 
Caplan wrote an editorial in “Addiction” (26) about the paradox of forcing treatment 
upon SUD patients: “Many would argue that the most significant achievement 
deriving from bioethics in the past 40 years has been to replace a paternalistic model 
of health provider–patient relationships with one that sees patient self-determination 
as the normative foundation for practice. This shift away from paternalism towards 
respect for self-determination has been ongoing in behavioral and mental health as 
well, especially as it is reflected in the ‘recovery movement’…Mandatory treatment 
which relieves the coercive effects of addiction and permits the recreation or re-
emergence of true autonomy in the patient can be the right thing to do.” 
In some mental disorders, including active phase psychoses, mania, and melancholic 
depression, the patient may have reduced ability to make autonomous decisions. 
Thus, a dilemma exists, and the pendulum has recently shifted towards more focus 
on personal autonomy. However, many countries still practice some form of 
involuntary treatment for SUD patients as an option of last resort (28, 29). Evidence-
based benefits of such interventions, outweighing the negative aspects of coercion, 
are needed to justify involuntary treatment.  
 
1.3 Involuntary admission to treatment 
Many concepts describe involuntary treatment in the literature, such as, compulsory 
treatment, detention, coercion, involuntary care and incarceration. They may be used 
in different settings and given different meaning. In this thesis, I chose to use the 
terms involuntary admission, involuntary treatment, and coercion. All IA patients 
included in the 3 studies were admitted to psychiatric hospitals with professional staff 
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and received treatment including detoxification and providing supportive environment 
during the stay; therefore I chose involuntary treatment rather than involuntary care. 
The Social Services Act does not provide access to the use of seclusion, restraint, or 
involuntary medication. Therefore, this kind of treatment is not a focus of this study. I 
use the authors’ original terms in direct quotes. 
In Norway, voluntariness is the dominant principle in the treatment of patients with 
SUD, but an option exists for involuntary admission to hospitals, if necessary, 
according to the two different laws mentioned below. 
According to the Norwegian Mental Health Care Act (§§ 3.2 and 3.3), compulsory 
psychiatric mental health care may occur when the patient is suffering from a 
suspected or established serious mental disorder (psychosis) in order to prevent 
severe deterioration of the patient’s health status or in cases in which an obvious 
threat exists to the patient’s own life or the life of others (22). In such cases, the 
patient may have reduced ability to make his or her own decision, i.e. reduced 
autonomy. Involuntary admission can only occur following examination by a 
physician. The hospital psychiatrist on duty examines the patient and accepts or 
rejects the referral. Within 24 hours, a psychiatrist or clinical psychologist makes the 
final decision on the legal basis for admission. When a patient is accepted for 
involuntary admission, it is as either observation, which can be extended up to 20 
days, or long-term detention for an indefinite period of time. To protect the patient’s 
personal autonomy, § 4-2 states that “restrictions and use of coercion shall be 
restricted to the absolute minimum”, and that “the patients’ views are to be 
considered”. Interventions may be used only when the positive effects of the 
intervention clearly outweigh its negative effects. In addition, when treated in an 
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institution, patients should make their own decisions regarding admission whenever 
possible (22). Many patients IA with serious mental disorders according to the Mental 
Health Care Act also have extensive problems with alcohol or drug abuse. However, 
problems with SUD alone are not sufficient for involuntary admission pursuant to the 
Mental Health Care Act if patients are not suffering from a psychosis.  
The other law, the Norwegian Social Services Act (§ 6.2), warrants involuntary 
interventions for non-psychotic adult patients with SUD (21). Municipal social 
services prepare the preliminary file, which is then submitted to the county social 
welfare board that makes the final decision regarding the application of involuntary 
treatment. The act covers an option for retention (up to 3 months) when the health of 
the patient is seriously at risk because of extensive and prolonged substance use 
and voluntary efforts have been shown to be insufficient. A separate provision on the 
detention of pregnant women suffering from alcohol or drug abuse, § 6.2a, can be 
ordered out of concern for the welfare of the unborn child. The law was updated in 
2012 (30). 
 
1.4 International practice 
A study by Israelsson and Gerdner based on three WHO reports published 1986 -
2001 found that 73 of 90 (82%) countries worldwide have laws on the involuntary 
treatment of substance abusers (29). The median duration of hospitalization for 
involuntary treatment was 2 years. According to the reports, the WHO defines 
compulsory treatment as treatment that do not require the person’s informed consent 
and excludes treatment that require informed consent within or as an alternative to 
being confined to prison. Three main legislative domains have been described as 
foundations for the mandated treatment of SUD patients: mental health care acts or 
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social services acts (in combination called civil commitment), and criminal justice 
acts. Although most countries may apply one or more of these acts to patients with 
SUD, not all countries provide all three alternatives (28). The majority of the countries 
use civil commitment, acute or rehabilitative, in accordance with welfare reasoning, 
whereas a minority of countries still use commitment under criminal law based on 
moral reasoning. Civil involuntary treatment is positively related to countries with 
strong economies or countries that were part of the former Soviet legal system. 
Involuntary treatment under criminal law is negatively related to the same factors and 
is still common in developing countries around the world (29). 
Israelsson also analyzed predictors of laws on involuntary admission to institutions 
and the types of legislation in 38 European countries (28). He found that a majority 
(74%) of the countries he evaluated had a law on involuntary treatment. The most 
common type of law was criminal justice legislation (45%), but civil law occurred 
almost as frequently (37%). According to Israelsson, these two models of legislation 
are related to differences in cultural heritage and welfare distribution models. 
Countries with a history of a strong temperance movement or a distribution of welfare 
through the state tend to favor civil law, whereas countries with a welfare distribution 
through insurance with less state interference now tend to favor criminal justice 
legislation (28). Israelsson provided an overview of the various laws used in Europe 
(Fig. 1). 
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Figure 1. Dominating laws on involuntary admission in Europe 
(28) (Printed with permission from S. Karger AG). 
 
1.5 Prevalence of involuntary admissions in Norway 
In 2010, approximately 8300 involuntary admissions were made to mental health 
care units in Norwegian hospitals according to the Mental Health Care Act. This 
constitutes 22% of all adult inpatients in mental health services (31). Despite the 
government’s efforts to reduce the use of involuntary treatment in mental health care, 
the numbers have remained unchanged in recent years. Thirty nine percent of the IA 
patients had schizophrenia as their main condition, and involuntary treatment often 
seems to be linked to this patient group (31). Approximately one out of three patients 
IA to mental health care hospitals had a SUD (10, 11, 32). To what degree these 
patients actually had a severe mental disorder in addition to SUD is not known.  
 
In 2010, only 106 decisions were made for involuntary admission to addiction units in 
Norway according to the Social Services Act. The number of such decisions 
increased between 1993 and 2010, but the number is still relatively low (Fig. 2) (33). 
Involuntary admission criminal 
Civil involuntary admission  
No law on involuntary admission  
Not included 
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Figure 2. Number of patients involuntarily admitted pursuant to the Social Services Act 
from the introduction of the law in 1993 to 2010 based on data from SiRUS, The Norwegian 
Institute for Alcohol and Drug Research (33). 
 
Significant differences exist in the use of involuntary admission according to both the 
Mental Health Care Act and the Social Services Act between and within different 
health regions. Theoretically, such differences could be explained by differences in 
population morbidity, but they more likely reflect differences in admission practices. 
Uncertainties also existed in the number of patients reported due to different and 
incomplete reporting praxis in different health regions (31, 34). 
In comparison, 1024 Swedish patients were IA during 2010 (population of 9.4 million 
compared to Norway’s 5 million) pursuant to the Swedish Social Services Act (35). In 
Denmark, SUD patients are restrained only by contract (36). However, similar to 
Norway, Denmark does have a mental health care act limiting the stay to 15 days, 
but the stay can be extended. The law may be used for alcohol- and drug-related 
psychoses (37). The map in Fig. 1 shows that Iceland does not have any law allowing 
coercion of SUD patients in treatment institutions. 
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1.6 Norwegian perspective and political guidelines 
In 2006, Norwegian politicians launched a national health plan to ensure quality and 
reduce the use of involuntary admission in mental health care (38). During the last 
few decades, focus on patients’ rights, empowerment, and participation has 
increased. Emphasis on individual autonomy and integrity has become the new trend 
(23). Patient involvement, at both the individual and system level, has become more 
common (39). Focus has also been placed on how health care providers can 
organize themselves in the most appropriate way to reduce involuntary admission 
through increased access to mental health services in emergency situations (40), 
systematic monitoring of patients with a history of long and complex mental 
disorders, and increased emphasis on patients' expertise in the design of treatment 
(38). The ability to reduce the use of involuntary admissions via legislative changes 
has also been considered, including whether to remove or change the treatment 
criteria. The current recommendation is that treatment criteria should be retained 
(41). The call for reductions in involuntary admission has, to date, not been based on 
scientific research. In Norway, no studies have shown that the use of involuntary 
admission is too high or applied inappropriately; however, the numbers of IA patients 
are consistently high. Most people would agree that agitated mania, psychosis, 
including homicidal psychosis, and severe depression require involuntary admission 
in some cases, but at the same time the level of involuntary admission should be kept 
as low as possible. Despite increasing focus both in Norwegian media and among 
politicians regarding IA patients, little has been said and done concerning the 
patients IA pursuant to the Social Services Act. This law was established in 1993 and 
revised in 2012, but little research has been done in the field to evaluate the 
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outcomes of the treatment, and no official guidelines are available on how to apply 
the law. However, one governmental report has focused on the importance of a more 
correct and consistent use of involuntary admission within the Social Services Act 
(42). 
We currently do not know much about the characteristics or outcomes of the patients 
IA pursuant to the Social Services Act. Are there more mental illnesses among 
patients with SUD who are IA than among those who are VA, or do IA patients 
experience more severe drug problems? Do IA patients with SUD have a greater 
burden of social problems or somatic diseases? Why are some SUD patients IA 
whereas others are not? 
 
1.7 Previous research 
1.7.1 Study designs in the field of involuntary treatment 
Involuntarily admitted SUD patients are generally a neglected group in the research 
literature. A review of relevant research on this issue includes both the Social 
Services Act and Mental Health Care Act. Due to ethical reasons, few randomized 
efficacy studies have focused on the involuntary admission of persons with SUDs. 
Randomizing patients into a group of IA patients who receive treatment and a group 
that does not receive treatment is difficult, though some examples exist (43). 
Therefore, other study designs are primarily used when such issues are explored. 
Often a comparison is made with voluntarily treated patients. The alternative to 
treating IA patients is normally not the treatment of VA patients, but no treatment at 
all (43). Most countries have their own legislation concerning involuntary admission to 
the hospital for patients suffering from an SUD alone or combined with mental 
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disorders. Therefore, legal and cultural differences make direct comparisons of 
studies across national boundaries difficult, and even comparisons between the 
Nordic countries. Clinical experience, resources, traditions, and attitudes vary 
considerably, even within the same county (23, 34, 44). Therefore, research should 
be performed locally to evaluate the local (national) outcomes of treatment practices 
and to guide policy in the field. 
1.7.2 International studies 
Wild et al. (2002) studied research trends in IA patients with SUD and presented an 
overview of a sample of 170 English language articles (45). Roughly half of the 
studies were non-empirical (e.g., literature reviews, policy proposals, legal and ethical 
commentaries on involuntary treatment). The reviewers reported on 18 quantitative 
comparative and longitudinal studies: eight studies were related to legal mandates, 
mainly involving offenders mandated to undergo or IA to treatment through the 
criminal justice system; five studies were formal mandates via coercion outside the 
criminal justice system (e.g., via the employer, welfare system); three were informal 
mandates (e.g., family, group persuasion); and two were mixed mandates (e.g., 
employers, informal family, court mandated). The studies were related to coercion or 
offenders identified through the criminal justice system. 
The reviewers reported that mandated treatment generally demonstrated better 
outcomes in terms of the treatment process (i.e., uptake of treatment following 
referral). The findings indicated more equivocal results for retention rates, with 6/11 
studies reporting higher participation for clients receiving compulsory treatment than 
those receiving non-compulsory treatment. In terms of substance use outcomes, two 
of eight studies found superior outcomes for clients receiving compulsory treatment 
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compared to voluntary treatment, whereas the other six studies reported no 
difference in benefits. However, the outcomes of mandated treatment demonstrated 
in these reports might not necessarily be the same as for patients involuntarily 
admitted pursuant to the Norwegian laws. 
 
Broadstock et al. (2008) commissioned a review of the effectiveness of involuntarily 
treating SUDs in non-offenders (46). For a comparison, no treatment, voluntary 
residential treatment, and involuntary outpatient/community-based treatment were 
included. Four review publications were eligible for inclusion and critically appraised, 
describing results primarily drawn from the literature on offenders. No primary 
research paper met the selection criteria for inclusion in the review. From the 
evidence-based studies that were identified, minimal evidence was available on the 
effectiveness of compulsory residential treatment of non-offenders alone. Some weak 
evidence was found to suggest that at least some people benefit from involuntary 
treatment. Many studies on involuntary treatment in populations that included 
offenders appear to report comparatively positive outcomes, but others less so. No 
evidence was found for involuntary treatment having advantages in outcome over 
voluntary treatment, or for harm by involuntary treatment. 
In a Norwegian report, Steiro et al. (2009) evaluated systematic reviews that included 
international, randomized, and controlled trials of IA patients dependent on opioids 
(47). The reviewers focused on the effects of the involuntary treatment of persons 
dependent on opioids and concluded that no study could be included in the review 
because none evaluated the effect of court-ordered substance abuse treatment in 
this group of patients. In addition, the design of the studies needed to be of higher 
  
16 
 
quality and include all phases of the continuum of care, from evaluation and 
treatment to aftercare. 
In Sweden, some relevant research has been performed in the field of involuntary 
admission. In 2004, Gerdner wrote a systematic review of 32 outcome studies (48),  
and in 2011, Gerdner and Berglund made an overview of international research 
studies (43). The main conclusion was that compulsory treatment increases the 
chances of completing the treatment program and aftercare. The outcomes of 
involuntary treatment and aftercare were as good as, or even better than, the 
outcomes of similar voluntary treatment for corresponding groups of patients. 
In her 2011 thesis, Lindahl studied court-ordered decisions regarding involuntary 
treatment of patients with SUD with respect to patients’ experiences and the outcome 
of care (49). The patients’ experiences with coercion during the investigation and 
treatment were studied. A total of 74 subjects who were either assessed prior to the 
court's decision on involuntary treatment (n = 39) or had previous experience with 
involuntary treatment (n = 35) were interviewed. Patients in the assessment group 
more often reported having the opportunity to express their opinions to the social 
worker during the assessment period and were more positive towards the final 
decision than patients from the group with previous experience. The clients who did 
meet with a social worker often described the conferences as being more of a 
perfunctory nature with a lack of focus on the actual situation and aftercare planning 
(50). 
Lindahl et al. also carried out a 2-year follow-up, investigating whether the global 
outcome and mortality differed between patients who resided in municipalities with 
low or high rates of involuntary treatment (51). The different ratios of involuntary 
treatment did not influence the global outcome and commitment was concluded to 
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reduce substance-related deaths. 
1.7.3 Norwegian studies 
We found two main directions when searching for Norwegian studies from the 
psychiatric field. The first direction concentrated on the prevalence of SUD in patients 
with mental health disorders admitted to psychiatric hospitals, the duration of stay, 
and prognosis, not taking into consideration whether the admission was voluntary or 
involuntary. A high prevalence of SUD (20-47%) was found among patients in 
security units and acute psychiatric units (9, 52, 53). Other researchers have used 
blood and urine tests to increase the detection of alcohol and drugs, finding even 
higher rates of substance use among patients with mental disorders admitted to 
acute psychiatric wards (26%-81%) (10, 11, 54).  
The second direction in psychiatric research has focused on involuntary admission to 
psychiatric hospitals. Focus has been placed on the relationship between involuntary 
treatment and the mental disorder (e.g., prevalence, patient’s perceptions, staff 
attitudes, treatment of the psychosis) with little attention on the comorbid SUD (44, 
55-62). 
In Norway, research from the addiction field is sparse when it comes to comorbid 
SUD and mental disorders, especially in regards to involuntary admission pursuant to 
the Social Services Act. A problem with prevalence research among patients from 
addiction centers is a lack of the routine use and evaluation of psychiatric diagnoses. 
A study of comorbid SUD and psychiatric diagnoses, the ROP study (Rus og 
Psykiatri), in two Norwegian counties using standardized tools found that patients VA 
to addiction centers had a high lifetime comorbidity of agoraphobia (48%), social 
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phobia (47%), and depression (44%) (63). Two-thirds of these disorders started at 
least one year before the SUD (64). In addition, 41% of the patients previously 
received treatment in psychiatric wards. 
A knowledge gap exists concerning involuntary admission pursuant to the Social 
Services Act. No proper evaluation has been performed regarding the consequences 
of the law, even though it was introduced almost 20 years ago.  
In Søviks’ dissertation “Detention of alcoholics or drug addicts – The Norwegian 
Social Services Act section 6-2 to 6-3”, the main question addressed the extent to 
which the society can prevent unwanted behavior among SUD patients by using 
involuntary admission (65). He stated that there were no qualifying criteria requiring 
serious or grave harm and that it is of concern who does make the decisions for 
involuntary admission to institutions and if it is made according to a fair and proper 
procedure. A more coherent legislation will hopefully lead to better conditions for 
growing group of patients with co-occurring SUD and mental diseases. Lundeberg et 
al. also wrote two reports on the use of the Social Services Act in cases of 
compulsory intervention among adult patients with SUD (34, 66). They examined the 
variations in organizational factors, such as leadership, human recourses, division of 
labor, and administrative tools, that determine and limit the extent to which 
involuntary admission is initiated. The most decisive factor in the application of the 
law was the intention to help individuals in a life-threatening situation. Social 
pressures were often an integral part of the process of seeking addiction treatment. 
Some of the SUD patients did not have any offer to further treatment on voluntary 
basis when the compulsory treatment was finished, even though they were 
motivated. If there are no arrangements that secure the patients’ rights to further 
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treatment, the purpose of the detention fails. However, the most critical factor under 
the present conditions is the legal protection of patients with dual diagnoses. 
A knowledge gap still exists when it comes to research focusing on patients with SUD 
who were IA pursuant to the Social Services Act. We have only been able to find one 
Norwegian report, from 1998, which showed that patients admitted to an institution 
according to the Social Services Act were more often females, and that they were 
younger than the men who were admitted to the ward (67). Most of the patients also 
used multiple drugs, especially the men, and often had comorbid severe mental 
disorders.  
In summary, we found that research in this field has generally been sparse and that 
the contributors have been individual researchers and small research groups from a 
few sites in Europe and the USA. Because laws and procedures are different 
between different countries, national studies are needed in order to evaluate the 
effect of involuntary admission. We need to identify which patients benefit from 
involuntary admission and perform follow-up studies to evaluate the effect of such 
treatment. Therefore, an evaluation of whether involuntary admission does fulfill its 
purpose and should be used more or less often is important.  
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1.8 Overall objective and aims 
 
The overall objective of this thesis is to investigate the relationship between 
substance use patterns and involuntary admission to hospitals in different settings 
pursuant to two different laws. Study 1 was carried out as a national study of SUD 
patients in acute psychiatric wards. Study 2 was carried out as a regional study of 
patients with FEP. The patients in Studies 1 and 2 were admitted to psychiatric wards 
pursuant to the Mental Health Care Act. Study 3 was a regional study of patients with 
SUD admitted to addiction treatment centers pursuant to the Social Services Act. 
The specific aims are:  
1. To describe and compare IA and VA patients with SUD according to 
sociodemographic characteristics in different settings. 
 
2. Examine whether typical patterns exist in the diagnostic comorbidity of 
SUD and mental disorders associated with involuntary admission. 
 
3. Investigate factors associated with the involuntary admission of patients 
with SUD to hospitals. 
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2.0 Materials and methods 
 
2.1 Data sources  
The papers presented in this thesis are based on data from three different samples. 
All of the papers focus on patients with SUDs who were IA to an institution. The 
background, methods, and samples for the three studies are presented below.  
 
Table 1. Summary of study designs. 
Study  Design Legislation Year of study Unit n = 
1  
National multicenter 
study, cross-
sectional  
Mental Health 
Care Act 2005-2006 
Psychiatric hospitals 
providing acute 
inpatient treatment 
3,506 
2  Comprehensive  2-year follow-up 
Mental Health 
Care Act 2002-2005 
Acute inpatient ward 
and outpatient clinics  103 
3  
Cross-sectional 
study with 
comparison of two 
groups 
Social Services 
Act 2009-2011 
Addiction treatment 
centers 202 
 
  
2.1.1 SUDs of patients admitted to acute psychiatric wards (Study 1) 
 
This study was part of the cross-sectional Multicenter study of Acute Psychiatry 
(MAP) in Norway (5). Data collection was carried out as a national cross-sectional 
study during 2005 and 2006 within a research network of acute mental health 
services. Data on patient characteristics and treatment episodes were collected from 
all patients admitted during a 3-month period. The network was organized and 
coordinated by the research institute SINTEF Health Research in Norway with 
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support from the Norwegian Directorate of Health and Social Affairs (56, 68). The 
sample originally consisted of 39 wards, which were categorized into three groups: 4 
admission wards, 28 acute wards, and 6 subacute wards. One ward was an 
intermediate term ward and removed from the sample, resulting in a total of 38 acute 
wards, which comprised 75% of Norwegian hospitals providing acute inpatient 
treatment at the time. The clinics were located in both urban and rural areas of the 
country and assumed to cover a representative sample of the Norwegian population 
(69). Data were collected from 3,506 admissions to adult acute psychiatric wards. 
Thirty-five percent of patients were IA to the hospitals (56). According to the Clinician 
Rating Scale, 1,187 of the 3,506 admissions were patients abusing psychoactive 
substances prior to admission. We found that 826 (70%) of the admissions were VA 
patients with SUD and 361 (30%) were IA patients with SUD (Fig. 3). 
Total 
n= 3506
Involuntarily 
admitted SUD 
patients
n=361 
SUD patients
n=1187
Voluntarily admitted 
SUD patients
n=826
No SUD patients 
n=2319 
 
Figure 3. Patients included in the MAP study. 
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2.1.2 Involuntarily admitted patients with first episode psychosis (Study 2) 
A large proportion of psychotic patients admitted to mental hospitals are IA. In Study 
2, we wanted to study whether these involuntary admissions were associated with 
SUD; and if so, whether special issues or characteristics of this population trigged the 
episodes.   
Study 2 included FEP patients in the southern sector of Rogaland County, Norway. 
Recruitment for the study continued consecutively from January 1, 2002, to June 27, 
2005. The criteria for inclusion were as follows:  
 Living in the catchment area  
 Age 15–65 years 
 Meeting DSM-IV (70) criteria for schizophrenia, schizophreniform psychosis, 
schizoaffective psychosis, delusional disorder, brief psychosis, affective 
disorder with mood incongruent delusions, or psychosis not otherwise 
specified  
 Being actively psychotic as measured by a Positive and Negative Syndrome 
Scale (PANSS) (6) score of four or more on at least one of the following 
PANSS items: P1 (delusions), P3 (hallucinations), P5 (grandiose thinking), P6 
(suspiciousness), and A9 (unusual thought content); not previously having 
received adequate treatment for psychosis (defined as antipsychotic 
medication of 3.5 haloperidol equivalents for 12 weeks or until remission of the 
psychotic symptoms)  
 No neurological or endocrine disorders related to the psychosis 
 No contraindications to antipsychotic medication 
 Understanding/speaking the Norwegian language 
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 IQ over 70 on the Wechsler Adult Intelligence Scale (WAIS) 
 Willing and able to give informed consent.  
The patients entered the study through the “Early Treatment and Intervention in 
Psychosis Study” (TIPS-II) low threshold detection team, or were referred to the 
hospital’s acute inpatient ward or outpatient clinics by local general practitioners or 
psychiatrists. After a preclinical screening interview, a senior psychiatrist or 
psychologist examined each patient. Demographics and supplementary information 
were collected, and a diagnostic interview was conducted. A total of 166 consecutive 
patients were identified. Twenty-three patients were excluded; nine were not 
registered in the catchment area, six had poor language skills, six were younger than 
15 years of age, and two had a low IQ. Of the 143 remaining patients, 39 refused 
participation (Fig. 4). Therefore, the rate of consent to participate was 73% (n=104 
patients). One patient was excluded later because of missing data regarding drug 
and alcohol use.  
Identified patients
n=166
Refused to participate
n=39
Insufficient data n=1
Not eligible n=23
9, not registered in catchment area
6, poor language skills
6, younger than 15 years
2, low IQ
Eligible patients
n=143
Included patients
n=103
Non- substance abuse 
n=78
Substance abuse
n=25
 
Figure 4. Patients included in the study of first episode psychosis. 
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The included patients were examined at baseline, after 3 months, and after 1 and 2 
years. All patients were assessed by trained personnel within a week of contact and 
assigned to the standard treatment program, which consisted of an antipsychotic 
medication algorithm, multifamily work, and active outreach-supportive 
psychotherapy (71). 
 
2.1.3 Involuntary admission of patients to addiction treatment centers (Study 3) 
This study is a cross-sectional study comparing IA and VA patients. The IA patients 
from three different treatment centers in the southeastern part of Norway were 
included: Kristiansand, Tønsberg, and Oslo, which have 4, 4, and 3 beds for IA 
patients, respectively. All of the VA patients were from Kristiansand from the same 
ward as the IA patients. The wards were multidisciplinary (i.e., psychiatrists, 
psychologists, social workers, occupational therapists, specialized nurses and other 
trained staff) and had specialized units that offered treatment for patients with primary 
SUD, which was often combined with mental disorders (except psychosis). The 
treatment focused on a structured interview and examination as the basis for a 
recognized diagnosis according to the ICD-10, pharmacotherapy, cognitive milieu 
therapy, and individual motivation enhancement for the patients. The population was 
mainly from urban and suburban areas. Recruitment to the study continued 
consecutively from January 1, 2008, to May 31, 2011. The criteria for inclusion were 
as follows: substance abuse or dependence based on ICD-10, age >18 years, 
understanding/speaking the Norwegian language, and a minimum 3 weeks of 
treatment. 
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Before inclusion, patients in both the IA group and VA group were detoxified, verified 
by negative urine tests for alcohol, opioids, central stimulants (amphetamines, 
methamphetamines, and cocaine), benzodiazepines, and cannabis or a minimum 14 
days spent in detoxification. Patients with mental retardation who were not able to 
understand the questionnaires were excluded. Pregnant patients were treated in 
special wards and not included in the study.  
A total of 202 consecutive patients were included in the study: 65 IA and 137 VA 
patients. Among the IA patients, 15 did not meet the inclusion criteria (12 due to too 
short of a stay and 3 due to low mental capacity), and 11 were not asked to 
participate due to logistic reasons at the treatment wards. Twelve of the eligible 77 IA 
patients refused to participate (Fig. 5). Therefore, the rate of consent to participate 
among IA patients was 84%.  
Identified IA-patients
n=103
Refused to participate
n=12
Not eligible n=26
12, to short stay  
3, low IQ
11, not asked
Eligible IA-patients
n=77
Included IA-patients
n=65
 
Figure 5. Involuntarily admitted (IA) patients in Study 3. 
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Among the VA patients, 72 patients were not included (69 due to too short of a stay, 
3 due to low mental capacity), and 14 of the 151 eligible VA patients refused to 
participate (Fig. 6). Therefore, the rate of consent to participate among eligible VA 
patients was 91%.  
Identified VA-patients
n=223
Refused to participate
n=14
Not eligible n=72
69, to short stay  
3, low IQ
Eligible VA-patients
n=151
Included VA-patients
n=137
 
Figure 6. Voluntarily admitted (VA) patients in Study 3. 
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2.2 Study instruments 
 
Table 2. Study instruments used in Studies 1, 2, and 3. 
 
In Norway, two medical classification lists are used to code diseases, signs and 
symptoms, abnormal findings, complaints, social circumstances, and external causes 
of injury or diseases: The Diagnostic and Statistical Manual of Mental Disorders, 4th 
Revision (DSM-IV) (2) and the International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10) (4). 
The ICD-10 was used for coding mental and behavioral disorders in Studies 1 and 3. 
The ICD-10 is maintained by the World Health Organization (WHO). In Study 3, all 
patients were subject to a clinical psychiatric examination supported by the Mini-
International Neuropsychiatric Interview (MINI), version 2002. The MINI is a short 
structured diagnostic interview for the assessment of psychiatric disorders according 
to the DSM-IV and ICD-10 classification systems (72) with high acceptance and 
validity (73, 74). The interviews were conducted by senior psychiatrists and 
 Method Study 
Tool 
Clinical 
interview/ 
observation 
Questionn
aire 
1  
SUD 
patients 
admitted 
to acute 
psychiatric 
wards 
2 
Patients 
diagnosed 
with first 
episode 
psychosis 
3 
Patients 
admitted 
to 
addiction 
treatment 
centers 
DSM-IV (SCID) X   X  
ICD-10  (MINI+) X  X  X 
PANSS X   X  
GAF X  X X  
Clinician Rating Scale X  X X  
ASI X    X 
SCL-90-R  X   X 
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psychologists with many years of clinical and research experience with the 
psychiatric assessment of patients with physical disorders.  
In Study 2, the Structured Clinical Interview for the DSM-IV (SCID) was used for 
diagnostic purposes (75). This tool is published by the American Psychiatric 
Association to provide a common language and standard criteria for the classification 
of mental disorders. SCID is used most extensively in the United States, but also to a 
varying degree around the world. The current version is the DSM-IV-TR (text 
revision) and organized into a five-part 'axis' system, with the first axis incorporating 
'clinical disorders' and the second covering personality disorders and intellectual 
disabilities. 
The PANSS is used for measuring symptom severity in patients with psychosis and 
was widely used in the study of FEP (24). In Study 2, we measured the psychotic 
symptom level using the PANSS. The symptom domains were represented by the 
corresponding PANSS components: positive, negative, excitement, cognitive, or 
depressive (25). The duration of untreated psychosis (DUP) was defined as the time 
from onset of psychosis until the start of adequate treatment. The onset of psychosis 
was equated with the first appearance of positive psychotic symptoms, defined as the 
first week with symptoms corresponding to a PANSS score of 4 or more on positive 
subscale items 1, 3, 5, or 6 or general subscale item 9. All available data sources, 
including semi-structured personal interviews with patients and relatives, were used 
to ascertain the length of this period. All raters were trained by rating prepared case 
notes and audio or videotapes before entering the study assessment teams.  
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Global Assessment of Functioning (GAF) (3) is a broadly used instrument for 
assessing the overall mental health of patients and was used in Studies 1 and 2 to 
rate social, occupational, and psychological functioning. GAF is from axis V in DSM-
IV-TR, and recorded values can be either a single score (i.e., only the most severe of 
the symptom and functioning values is recorded) or separate scores for symptoms 
(GAF-S) and functioning (GAF-F). 
 
The Symptom Checklist-90-R (SCL-90-R) instrument was used in Study 3 to evaluate 
the range of psychological problems and symptoms of psychopathology (76). The 
test contains 90 items, measures nine primary symptom dimensions (somatization, 
obsessive-compulsive, interpersonal sensitivity, depression, anxiety, anger/hostility, 
phobic anxiety, paranoid ideation, and psychoticism). The SCL-90-R provides an 
overview of a patient's symptoms and their intensity during the previous 7 days. Each 
of the 90 items is rated on a five-point Likert-type scale, ranging from “not at all” 
(score = 0) to “extremely” (score = 4): higher values indicate greater symptom 
severity during the past week. The Global Symptom Index (GSI) score was used to 
assess the overall level of general psychological distress. 
In Studies 1 and 2, drug and alcohol use during the 6 months prior to the index 
hospital admission were assessed by the Clinician Rating Scale (Alcohol Use Scale 
and Drug Use Scale) (12, 77). This rating scale is used to measure the consumption 
of psychoactive substances on a scale from 1 to 5 (1 = no use, 2 = use without 
impairment, 3 = abuse, 4 = dependence, and 5 = dependence with need for 
institutionalization). The use of psychoactive substances without impairment is 
defined as “no evidence of persistent or recurrent problems in social functioning, 
  
31 
 
legal status, role functioning, mental status, or physical status, and no evidence of 
recurrent dangerous use”. The patients were subsequently divided into two groups:  
1. The non-substance abuse group including patients who scored 1 or 2 on the 
Clinician Rating Scale (for alcohol and/or drugs).  
2. The substance abuse group including patients who scored 3, 4, or 5 on the 
Clinician Rating Scale (for alcohol and/or drugs).  
 
Sociodemographic variables were measured in Study 3 using the European 
Addiction Severity Index (ASI). This tool is a personal, structured interview designed 
for both clinical and research purposes that includes seven areas: medical status, 
employment and support status, drug and alcohol use, legal status, family history, 
family and social relationships, and psychiatric status (1). Trained and certified staff 
performed the ASI interviews. Specific substance use patterns were dichotomized 
into drug consumption at least once a week versus less than weekly.  
 
2.3 Data analysis 
 
Table 3. Statistical analyses used in papers I, II and III. 
  Paper 
    I II III 
Statistical analysis Mean (standard deviation) X X X 
 Median  X  
 Chi-square test  X X 
 Student’s t-test X X X 
 Fisher's exact test  X X 
 Wilcoxon Signed Rank test  X  
 Mann–Whitney U-test  X  
 Spearman's rho  X X 
  Multivariate logistic regression X X X 
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Continuous variables are reported with means and standard deviations (SDs). 
Categorical variables are reported as frequencies. The independent sample t-test, 
chi-squared test, and Fisher’s exact test were used to test for significant differences 
between groups. Data that were not normally distributed were analyzed with a non-
parametric test (Wilcoxon Signed Rank test and Mann–Whitney U-test). Logistic 
regression (enter model) was performed to investigate the relationship between IA 
and VA patients and specific substance-related diagnoses (Study 1), involuntary 
treatment outcomes (Study 2), and patient characteristics (Study 3). In Study 2, the 
DUP did not seem to have a normal distribution, whereas its natural logarithm did. In 
multiple logistic regression analysis, DUP was transformed to its natural logarithm. 
Results are presented with 95% confidence intervals (CIs). The continuous variables 
were checked for correlation with Spearman’s rho. None of the continuous variables 
that were included had a correlation exceeding 0.7. In Study 3, the number of cases 
in the sample restricted the predictors included in the model. Variables from the 
univariate analysis with P < 0.10 were included in the multivariate analysis, except in 
Study 3 “overdoses on drugs” because of multicollinearity with the variable “injecting 
illicit drugs”. The threshold for significance was P < 0.05. Analyses were performed 
using SPSS 16.0 or 18.0 Software (SPSS Inc., Chicago, IL, USA). 
 
2.4 Ethics 
The Norwegian Directorate of Health and Social Affairs provided permission to collect 
information from health services. Study 1 was approved by the Regional Committee 
for Medical and Health Research Ethics and the Data Inspectorate, Oslo, Norway; 
the National Committee for Research Ethics in Norway (REK 211-04049); and the 
Privacy Issues Unit, Norwegian Social Science Data Services (NSD no. 11074). The 
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Regional Committee for Medical and Health Research Ethics approved that data 
could be collected without asking for consent, as it was considered ethically important 
to include IA patients independently of consent to participate. The Regional 
Committee for Medical Research, Ethics Health Region West (REK 015.03) approved 
Study 2. Study 3 was approved by The National Committee for Research Ethics in 
Norway, Region South East (REK 08/206d, 2008/2900, 09/2413) and the Privacy 
Issues Unit, Norwegian Social Science Data Services (NSD no. 18782).  
Anonymity occurs when the researchers cannot link participants to their data and is 
the most secure means of protecting confidentiality. Anonymity was present in 
Studies 1 and 2. When anonymity is impossible, such as the case in Study 3, patients 
are given a pledge of confidentiality, which means that the information participants 
provide will not be made accessible to unauthorized persons outside the project 
group. Data were kept inside the hospital’s secured network for the strictest 
confidence, and identification numbers substituted participants’ names in the 
computer files. 
A superior ethical principle for protecting study participants is respect for human 
dignity and the right of self-determination, which encompasses people’s right to make 
informed, voluntary decisions about participation. Participants in Studies 2 and 3 
received written information. The respondents provided informed consent, which 
means that adequate written and oral information was provided, and patients were 
informed that refusing to participate in the study would not interfere or have negative 
consequences with respect to any aspect of treatment. Written informed consent was 
obtained from all study participants in both studies. In Study 2, parents or legal 
guardians gave informed consent for patients younger than 18 years of age.  
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The ability to provide adequate information is also dependent on whether the 
recipient is in a state in which they are able to understand the information. For the 
consent to be valid in Study 3, patients could not be in an acute detoxification phase, 
which allowed them to be informed in a situation of sufficient cognitive ability and 
gave them the power to make a free choice concerning study participation. 
Therefore, to be included in the study, the patients were in treatment at least 3 
weeks. 
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3.0 Results 
This section responds to the specific aims of the thesis. The results are sometimes 
presented in a slightly different manner than in the papers I-III. The selection of 
patients was different in each of the three studies. Study 1 was a large national study 
of all patients admitted to acute psychiatric wards. Study 2 was a regional study of a 
selected patient population with FEP. Study 3 was a study of selected patients with 
SUD admitted to addiction treatment units.   
 
3.1 Aim I 
To describe and compare IA and VA patients with SUD according to 
sociodemographic characteristics in different settings. 
Baseline sociodemographic variables are presented in Table 4. 
 
Table 4. Baseline sociodemographic variables. 
 Study 
  1 2 3 
 SUD patients admitted 
to acute psychiatric 
wards 
Patients diagnosed with 
first episode psychosis 
Patients admitted to 
addiction treatment 
centers 
Patients Involuntarily admitted 
Voluntarily 
admitted 
Involuntarily 
admitted 
Voluntarily 
admitted 
Involuntarily 
admitted 
Voluntarily 
admitted 
n (%) 361 (30) 826 (70) 42 (41) 61 (59) 65 (32) 137 (68) 
Male, % 64 63 55 56 52 73 
Age, mean years (SD) 37 (12) 34 (12) 25 (10) 26 (10) 29 (11) 31 (9) 
Living with a partner, % 15 18 15 16 13 9 
Employed, % 9 10 5 23 10 19 
 
In Study 1, we found that two-thirds of both IA and VA patients with SUD were males, 
with a mean age of 34 years and 36 years, respectively. Only 15% of the IA patients 
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and 18% of the VA patients were living with a partner, and only 9% of the IA and 10% 
of the VA patients were employed.  
 
In Study 2, we found that more than half of FEP patients with SUD were males. The 
patients were relatively young, and few were living with a partner. Among patients 
with FEP, 23% of the VA and only 5% of the IA patients were employed. However, 
29% of the IA patients and 21% of the VA patients reported being students.  
 
We found the largest gender difference in Study 3; 52% of the IA patients were men 
compared to 73% of the VA patients (Table 4). Thus, in Study 3, female patients 
were relatively more often IA (48%) than VA (27%) (P = 0.004). Only 13% of the IA 
and 9% of the VA patients were living with a partner, and 10% of IA and 19% of VA 
patients were employed.  
 
In summary, when comparing the sociodemographic characteristics of patients in the 
three studies, we found that men constituted the majority of all three samples, 
regardless of voluntary or involuntary status. Also, the majority of patients were 
relatively young, between 20-30 years of age. The oldest patient population was 
found in the national study of patients admitted to acute psychiatric wards (Study 1), 
and the youngest patients were the FEP patients in Study 2. No significant age 
difference was found between IA and VA patients. In all three studies, we found that 
very few patients were living with a partner, employed, or had higher education.  
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3.2 Aim 2 
Examine whether typical patterns exist in the diagnostic comorbidity of SUD and 
mental disorders associated with involuntary admission. 
 
Figure 7. Distribution of involuntarily and voluntarily admitted patients with comorbid SUD 
and mental health disorders. Study 1 (Patients admitted to acute psychiatric wards), 
Study 2 (Patients diagnosed with first episode psychosis), Study 3 (Patients admitted to 
addiction treatment centers). *Including SUD and non-SUD 
 
In Study 1, we investigated all patients (both SUD and non-SUD) admitted to acute 
psychiatric wards and found that approximately one-third of the patients had a 
comorbid SUD and mental health disorder (Fig. 7). We found that the most frequent 
substance use diagnosis among patients IA to acute psychiatric wards was F19, 
multiple drug diagnoses (ICD-10). The use of alcohol, stimulants, and opiates was 
the most frequent single substance use diagnosis. Study 1 provides a general 
impression of acute psychiatric patients in Norway (mixed with respect to diagnosis). 
The most frequent diagnoses were schizophrenia disorders, followed by mood 
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disorders and personality disorders. Seventeen percent of the patients had more 
than one psychiatric diagnosis (Table 5). 
In Study 2, we found that only 12% of the VA FEP patients had a comorbid SUD. 
However, comorbidity was much more frequent among the IA patients. By inclusion, 
all patients in Study 2 had FEP (89% schizophrenia and 11% mood disorders). Some 
of the patients might have had more than one psychiatric diagnosis, but those data 
were lacking. Alcohol, cannabis, and stimulants were the most frequently used 
substances among FEP patients.   
In Study 3, the majority of the patients admitted to addiction treatment centers 
experienced comorbidity. More than two-thirds of the patients IA pursuant to the 
Social Services Act reported using three or more substances. Benzodiazepines, 
amphetamine, cannabis, and alcohol were the most commonly used substances in 
this group. The most frequent diagnoses among IA patients with SUD were neurotic 
disorders, attention-deficit hyperactivity disorders (ADHD), and mood disorders. More 
than one-fourth (26%) of these patients were diagnosed with multiple psychiatric 
diagnoses (Table 5).  
The most frequent mental diagnoses among IA patients with SUD in all three studies 
are presented in Table 5.  
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Table 5. Per current ICD-10 psychiatric diagnoses of patients with SUD and 
involuntarily admitted to hospitals. 
  
Study 1 Study 2 Study 3 
SUD patients 
admitted to 
acute 
psychiatric 
wards 
Patients 
diagnosed with 
first episode 
psychosis 
Patients 
admitted to 
addiction 
treatment 
centers 
 n=94 n=18 n=39 
F20-F29 Schizophrenia disorders, % 42 89 8 
F30-F39 Mood disorders, % 17 11 14 
F40-F49 Neurotic disorders, % 6 - 28 
F60-F69 Personality disorders, % 16 - 12 
F90-F99 ADHD*, % 0 - 17 
Multiple mental disorders, % 17 - 26 
Other mental disorders, % 2 - 5 
*Attention-deficit hyperactivity disorders 
In summary, a large proportion of the patients in all of the studies had comorbid 
psychiatric disorders and SUDs characterized by multiple drug use. Alcohol, 
cannabis, and stimulants were the most commonly used substances in all three 
studies. However, the types of psychiatric diagnoses were very different between the 
three patient populations (Table 5). 
 
3.3 Aim 3 
Investigate factors associated with the involuntary admission of patients with SUD to 
hospitals. 
In all three studies, multiple logistic regression analysis was used to investigate 
possible differences between the IA and VA patients, controlling for relevant 
covariates. SUD influenced involuntary admission to hospitals in all three studies. In 
Study 1, being IA to acute psychiatric wards was significantly associated with the use 
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of stimulants (OR 2.3, 95% CI 1.266-4.099, P = 0.006). In Study 2, both SUD and 
non-SUD patients with FEP were included in the analysis. SUD was significantly 
associated with involuntary admission during follow-up (OR 5.2, 95% CI 1.654–
16.498, P = 0.005). In Study 3, we found that patients IA to addiction treatment 
centers pursuant to the Social Services Act were characterized by more severe, long-
term drug addiction than the VA patients. The IA patients were more often females, 
receiving public welfare benefits, and frequently visiting physicians for somatic 
complaints. Neither the severity of the mental illness nor the number of substance 
use diagnoses was associated with being IA.  
In summary, in all three studies, we found that both VA and IA patients pursuant to 
either the Mental Health Care Act or the Social Services Act were typically males, 
relatively young, and living without a partner. A large proportion of the patients had 
comorbid psychiatric disorder and SUD characterized by multiple drug use. The 
presence of SUD influenced involuntary admissions to hospitals in all three studies. 
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4.0 Methodological considerations 
 
The quality of the results of any epidemiological investigation is dependent on the 
methods used for sampling and measurement. Random error can be defined as the 
lack of precision due to high sampling variability (78). Selection bias (i.e., systematic 
error) is the difference between an observed value and the true value due to all 
causes other than sampling variability, such as selection and information 
measurement biases (79). For a study to be considered valid, the random and 
systematic errors should be minimal (78). Validity is divided into the concepts of 
internal and external validity. For descriptive studies, internal validity refers to the 
accuracy or quality of the study (i.e., how well the study was run in terms of research 
design and how variables were measured), and external validity is the extent to which 
the results can be generalized to larger populations and contexts outside the study 
sample (80, 81). The sources of these errors, the actions taken to reduce such 
errors, and the implications of the errors on our results and conclusions are 
discussed below. 
 
Several methodological issues merit discussion in this thesis. The issue of 
involuntary treatment itself somewhat restricts the method choices. Ideally, the 
patients should be randomized into two different groups, with one group receiving 
involuntary treatment and the other group not receiving any treatment. Due to ethical 
considerations, randomization cannot be used when focusing on the involuntary 
treatment of patients with SUD. Studies comparing involuntarily treated patients with 
voluntarily treated patients contribute to our knowledge about differences in social 
characteristics, SUDs, comorbid mental disorders, and treatment outcomes, as well 
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as reasons leading to involuntary admission. In such studies, the type of control 
group and what kind of conclusion can be drawn should be carefully considered. In 
Studies 1 and 3, IA patients were compared with VA patients. We cannot rule out that 
this approach may have biased the results, but social characteristics were 
comparable in both groups and the VA patients had all been considered to qualify for 
treatment in a hospital. If a measure of ”motivation for treatment” had been available 
for both IA and VA patients in the two studies, we could have adjusted for that 
potential confounding factor, but unfortunately such data were not available. 
 
4.1 Design 
Studies 1 and 3 both had a cross-sectional study design in which the collected 
information for both dependent and independent variables referred to the same point 
in time (82). Both studies compared VA and IA patients treated in hospitals. This 
design limits inference to causality, though measuring the strength of the association 
between independent and dependent variables is possible, but determining which 
one preceded the other is not (83). Study 2 had a longitudinal study design. We 
collected information both at inclusion and at the one and two-year follow-up.  
 
4.2 Selection bias 
Selection bias is a systematic error in a study that stems from the procedures used to 
select subjects and from factors that influence study participation (82). Some 
variations occurred between the three studies in the percentage of included patients. 
In Study 1, the sample originally consisted of 38 acute psychiatric wards across all 
five health regions in Norway, which comprised 75% of Norwegian hospitals 
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providing acute inpatient treatment and results in a completeness of data considered 
to be representative of Norwegian acute psychiatric wards (5, 84). Patients were 
included over a 3-month inclusion period. This study did not require informed consent 
from the patients as only routine data were registered in the dataset. Almost all wards 
succeeded in including all patients admitted during the inclusion period. 
Approximately 95% of all patients admitted during the inclusion period are estimated 
to have been included in the material (56). 
 
In Study 2, all FEP patients in a particular region during a specific time period were 
invited to participate in the study, and only 39 patients refused. No significant 
difference was found between those who refused to participate and those who were 
included in regards to age, gender, or duration of untreated psychosis. These are the 
core variables that indicate a lack of significant differences between the two groups. 
Limited data were available for the patients refusing to participate because the data 
were anonymized and the patients did not consent to a more comprehensive 
assessment. 
 
In Study 3, the population was a specific SUD sample. The included patients were 
from three different publicly funded addiction treatment centers. The assessment was 
introduced to the wards as a routine tool. Therefore, all patients completed the same 
tests but chose whether these results could be included in the research project. This 
approach led to a high study participation rate. The rate of consent to participate was 
84% among IA patients and 91% among VA patients. Information on the 
sociodemographic data for excluded patients was not available. Among the IA 
patients, 26 were not eligible and 12 refused to participate. These patients did not 
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differ according to age and gender. A total of 223 VA patients were identified, 72 of 
whom were not eligible because of too short of a stay in the treatment centers. The 
drop-out analysis showed that included and excluded VA patients did not differ 
according to age, but the proportion of women was somewhat higher among 
excluded patients than included patients (35% vs. 27%).  
The reasons why VA patients did not complete the treatment may be complex. 
During the first days of treatment, some patients developed a need for another type 
of treatment and were transferred to different wards. Other patients experienced drug 
cravings and wanted to leave, whereas some had problems with family caring or 
conflict, or even caring for animals. Some patients just said that they were less 
motivated, and that this was not the right kind of treatment for them, so they would 
prefer to be treated somewhere else. Some patients said that they were now in 
control of their situation and able to manage on their own. However, the staff 
considered some of these patients as not having insight into their own SUD and 
accompanying ambivalence. A few patients exhibited threatening or violent behavior 
towards other patients or staff. For safety reasons these patients were asked to leave 
the ward.  
In summary, our findings may indicate that the VA patients who did not participate 
differed from the included patients in that they had more severe symptoms. 
Therefore, the results of the VA patients may tend to underestimate the burden of 
pathology. Thus, the comparison with the IA group may be characterized by a 
tendency for greater differences between the groups than would have been the case 
if the non-responders among VA patients had been included. 
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Nevertheless, in all three studies, the non-participants were not indicated to differ in 
any major direction from the participants, and selection bias likely did not influence or 
substantially affect the main findings and conclusions.  
 
4.3 Information bias 
 
Bias is the difference between the sampling value and the true population value. 
Systematic error can occur in a study because the information collected about or 
from the study subjects is erroneous (82). As the MAP study (Study 1) was a 
multicenter study, some methodological limitations need to be considered. Many staff 
members were involved in collecting the data, which could be a weakness because 
we do not know if they interpreted the questionnaires in the same way. The study did 
not include procedures to secure inter-site reliability, but written information about the 
study and education about using the instruments were given to all staff members. 
Another weakness could be that we did not have any data to decide whether some 
patients were admitted more than once during the inclusion period. However, the 
inclusion period was only 3 months, and the number of patients admitted more than 
once would be small; therefore, the issue of independent informants is expected to 
have little influence on the results. 
In Study 2, we tried to avoid information bias using identical instruments with 
assessments performed by the same raters. All raters underwent an education 
program that included procedures to secure the inter-rater reliability in regards to 
both diagnosis and the description of symptom severity. 
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In Study 3, trained and certified staff members interviewed all patients. Standardized 
training was performed to ensure good quality data. Most patients expressed positive 
attitudes towards participation in the study, and even patients burdened by significant 
mental symptoms were able to regain control and become focused during the 
research interview. This ensured that even patients with the highest burden of 
morbidity were included in the study. The raters made comments if any conflicts or 
untrustworthy information were found in the collected information. 
In all three studies, a risk of recall bias existed (82); the information that was obtained 
might have been affected by the patient’s memory. The questions often concerned 
matters that happened a long time ago. In general, the patients did remember very 
well when they started using drugs, but it was more difficult for them to remember 
exactly when the drug use escalated. The description of substance use relied mostly 
on the patient interviews and recall, supplemented by collateral information; 
therefore, substance use may have tended to be under-reported in our studies. 
Despite the fact that the estimates of substance use may have been conservative 
estimates, we observed significant associations between substance use patterns and 
involuntary treatment in all three studies, indicating that the associations were 
relatively robust. 
4.3.1 Social desirability 
Social desirability may be an important form of information bias. The patient’s 
response can be influenced by what he or she thinks is the correct answer and 
whether it was the patient’s own therapist or someone outside the institution that 
conducted the interviews. Missing information and misclassification could both be 
problems if the patients were thinking that the information revealed during the 
interviews could entail any negative consequences. A SUD is more likely to be under-
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reported than over-reported due to the social stigma associated with the conditions 
(85-87). Therefore, one bias could be that, by admitting current substance use, VA 
patients might fear losing their treatment options. However, the studies in this thesis 
focused on substance use patterns prior to admission to treatment and would not 
result in any consequences. Theoretically, patients could still report lower 
consumption rates than their actual consumption patterns. As such, our studies are 
likely based on minimum estimates. 
 
Routine biomedical screening of specific alcohol and drug diagnostic tests can be 
used to increase the validity of information obtained regarding substance use 
patterns. Studies comparing urine analysis to routine clinical practice, such as 
structured interviews and patient self-reports, have demonstrated a general tendency 
for under-detection of recent substance use among patients admitted with acute 
psychiatric disorders if no biomedical screening is included (87, 88). In our studies, 
no biomedical screening was included.  
 
4.3.2 Reliability 
Reliability is the consistency of a measurement tool. The reliability of a scale 
indicates how free it is of random error. Two frequently used indicators of a scale’s 
reliability are test-retest reliability and internal consistency. The test-retest reliability of 
a scale is assessed by administering it to the same persons on two different 
occasions and calculating the correlation between the two scores (89). Internal 
consistency is the degree to which the items that make up the scale all measure the 
same underlying attribute (89). In the three studies, we used several different 
measurement tools. The two main tools were the ASI and the Clinician Rating Scale, 
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which were used to assess the substance abuse found among alcohol- and drug-
using patients included in the studies.  
The ASI has been used widely during the past few years in drug and alcohol 
treatment settings. The reliability and validity of the ASI are well documented (90, 
91). Studies have shown that the interobserver reliability of ASI composite scores is 
satisfactory when sufficient data are available (91, 92). However, Makelas’ review of 
the literature questions the reliability found in some contexts (93). Furthermore, data 
quality control can be a neglected issue in some studies (89). However, all of the 
raters participating in the studies were trained and certified to perform the ASI 
interviews in order to improve reliability. A telephone number was available to call if 
the raters were uncertain of anything, and they were also offered a follow-up course 
in which problems could be discussed, though the lack of formal testing for reliability 
is a weakness.  
The Clinician Rating Scale has been proven reliable, sensitive, and specific when 
used by case managers following clients over time (77, 94). The test-retest 
reliabilities for small samples over 1 to 2 weeks are close to 100%. Inter-rater 
reliabilities established by comparing the ratings of clinical case managers and team 
psychiatrists have yielded Kappa coefficients between 0.85 and 0.95 for SUDs (94). 
When Clinician Rating Scale ratings were compared to consensus diagnoses 
generated by a team of experienced psychiatrists using all of the clinical and 
research data available for each client to establish a current diagnosis of substance 
abuse or dependence, the Clinician Rating Scales achieved high sensitivity (94.7%) 
and specificity (100%) (77). In Study 2, all raters were trained by rating prepared 
case notes and audio/videotapes before entering the study assessment teams. The 
reliability of measurements ranged from poor to very good (Cronbach’s alpha) (89) 
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[DUP, 0.99; GAF-S score, 0.68; GAF-F score, 0.45; drug abuse, 0.67; alcohol abuse, 
0.81 (all intraclass correlations, 1.1); and for diagnostic categories K = 0.58]. In Study 
2, the GAF-F score was removed from further analysis due to poor reliability (95). 
Nevertheless, the data in all of our studies were checked for errors and the 
frequencies of each of the variables inspected before analysis. In Study 3, three of 
the SCL-90-R questionnaires had a value outside the range of possible scores due to 
incorrect data entry in the data file. The errors were corrected.  
4.3.3 Confounding 
Confounding could simply be defined as confusion, or the mixing of effects; this 
implies that the effect of the exposure is combined with the effect of another variable, 
leading to bias (82). The two main strategies for handling confounding in research 
are to stratify analyses according to the potential confounding factor or to perform 
multivariate analysis. In these studies, we were investigating the relationship between 
involuntary admission and SUDs. Patients with SUD generally constitute a very 
heterogeneous group of patients, including patients with independent mental 
disorders complicated by substance use to patients with only psychoactive 
substance–induced disorders. In the present studies, multivariate analyses including 
known potential confounders were applied. However, “unknown” potential 
confounders may still bias the results (e.g., IQ, premorbid functioning, education), 
though we are not aware of any such factors that could have altered the presented 
results in any major way. 
Neuropsychological functioning is one possible confounding factor that we were not 
able to control for. Patients in Studies 2 and 3 were offered such testing, but too 
many refused to participate. Therefore, the results were not included.  
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4.4 Strengths 
The three studies included in the thesis have several strengths. Standardized and/or 
established instruments were used in all studies, which allows the result to be 
compared to similar populations or other patient groups. The studies had a high 
inclusion rate, probably due to the data collection in most wards representing a 
standardization of initial examinations included in the wards’ consecutive procedures. 
Study 1 was a large study including 75% of all acute wards in Norway; thus, informed 
consent was not necessary and we did not lose any patients due to refusal to 
participate. Study 2 had only a 15% drop-out rate during the 2-year follow-up period.  
 
4.4.1 External validity 
External validity refers to the extent to which the results of a study can be generalized 
or extended to other studies (96). The process of generalization involves making 
assumptions about the domain in which the study results apply and is often a 
question of whether the studied factors distinguish the studied groups from other 
groups and somehow modify the results from the study (89). Before generalizing the 
findings reported in our studies, recognizing that differences might exist between the 
cohort of studied patients with SUD and the cohort of patients that was being treated 
(i.e., the target population) is important. The frequency of the involuntary 
hospitalization of patients varies between and even within different countries and is 
dependent on legislation, clinical experience, resources, traditions, and attitudes (34, 
44).  
The large data collection in Study 1 represents the diagnostic reality in a large 
number of clinical settings in Norway, not only in a strictly controlled experiment. The 
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sample is large compared to other international studies and may have the power to 
detect clinically significant associations. The findings can be generalized to SUD 
patients IA to hospitals according to the Mental Health Care Act in Norway, and 
probably even to other countries with similar laws. 
Study 2 had a smaller sample size but was controlled for population variance via the 
selection of samples from the same healthcare sector within a short timeframe (1-
year differences). No private institutions were present in the catchment area; 
therefore, we can assume that the obtained samples were very similar to an 
epidemiological sample in terms of the incidence of FEP. However, incidence was 
not the focus of Study 2. The included FEP patients were assumed to share similar 
characteristics, including substance use patterns, with FEP patients from other parts 
of Norway. Therefore, the presented findings can be generalized to other Norwegian 
populations of FEP patients. 
A previous study from Norway showed that social services in different regions have 
different procedures regarding the use of involuntary admission pursuant to the 
Social Services Act (34). These differences can cause the threshold for admission to 
vary, and patients from different regions may present with different functional levels 
of physical health, psychological health, drug abuse, and social skills. In Study 3, the 
included patients were referred to the institutions from social service offices from 
Southern Norway pursuant to the Social Services Act, not from a specific region. A 
choice of hospital was not offered to this group of patients, so there was no selection 
to preferred institutions, and the included patients were considered to be a fair 
selection of patients from several regions. In addition, the total number of patients 
being IA according to this act in Norway is relatively low (33). Therefore, the relatively 
large sample size in Study 3 compared to all patients admitted based on this act 
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could likely be considered to be representative of patients IA according to the Social 
Services Act in Norway.  
 
Overall, the associations presented in the three studies are considered relatively 
robust, as the overall impression from the studies was that no major known 
mechanisms of selection bias or confounding occurred, though it cannot be ruled out.   
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5.0 Discussion of results 
 
The discussion is based on Aims 1 – 3. First, sociodemographic characteristics, 
including gender, age, marital status, and employment, are discussed. Thereafter, 
comorbid mental disorder and SUD is discussed. Finally, factors associated with 
involuntary admission are discussed.  
 
5.1 Aim 1 
5.1.1 Gender distribution 
In psychiatric hospitals in Norway, a typical gender distribution of more women than 
men is found among inpatients (97). However, men are more often AI (56, 98). 
Overall, 64% of substance users IA to acute psychiatric wards pursuant to the Mental 
Health Care Act are males (99). In Norway, approximately 70% of persons with SUDs 
are men (97, 100). We found that 52% to 73% of the patients in our three studies 
were men (Table 4). Though the majority of substance users in Study 3 were males, 
we observed nearly twice as many females among the IA patients compared to the 
VA patients. Social workers have reported that the reason for the relative majority of 
female patients in involuntary addiction treatment might be that service providers 
consider women more vulnerable with exposure to violence and prostitution (34). The 
opposite sex distribution was reported by the Swedish National Board of Institutional 
Care; only one-third of the substance users in compulsory care pursuant to the 
Swedish Law on Care of Misusers were women (35).  
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5.1.2 Age 
The mean age of the patients in the three studies varied from 25 to 37 years (Table 
4). The lowest mean age was found among IA patients with FEP (Study 2). This 
finding was expected because we examined a selected population of patients with 
their first episode of psychosis, which typically occurs in younger persons. Our 
findings in all the three studies are in accordance with Barnes et al., who found that 
patients with a reported lifetime history of substance use were significantly younger at 
the time of assessment, as well as at the onset of their psychotic symptoms (101). 
 
5.1.3 Marital status 
One of the reasons why mental disorders cause adverse life course consequences is 
via impairment of a person’s ability to form and maintain social relationships, 
including marriage. Marriage confers a variety of benefits (102). In Norway, couples 
also commonly live together without being formally married. In our studies, we found 
that the number of patients living with a partner was relatively low, varying from 9% to 
18% (Table 4). This finding is in accordance with Breslau et al.’s study; across 19 
countries (low-, medium-, and high-income countries), mental disorders were 
associated with a lower likelihood of marriage (102). 
 
5.1.4 Employment 
The majority of the patients in all three studies were unemployed. The employment 
rates varied from 5% to 23% (Table 4). Notably, only 5% of the IA patients with FEP 
reported being employed.  
Patients with serious mental illnesses and comorbid SUD are often excluded from 
vocational services, despite the lack of evidence that having a SUD necessarily 
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prevents them from being able to work (103). Frounfelker et al. found that, despite a 
similar interest in employment, clients with comorbid SUD were 52% less likely to 
enroll in a supported employment program than those without SUD. Patients who 
were enrolled had similar competitive employment rates: 25% for those with 
comorbid disorders and 28% for those without (103). 
 
In summary, we found that both VA and IA patients, pursuant to either the Mental 
Health Care or the Social Services Act, were typically males, relatively young, 
unemployed and not living with a partner.   
 
5.2 Aim 2 
Comorbid psychiatric disorders among patients with SUD are highly prevalent and 
have been linked to serious negative health consequences (104-110). In our studies, 
the proportion of SUD patients with comorbid mental health problems among the IA 
patients varied from 32% to 60%, and from 12% to 75% among the VA patients (Fig. 
7). In Study 1, we found that approximately one-third of the patients (IA and VA 
patients) in acute psychiatric wards had comorbid SUD and mental health disorders. 
Overall, fewer FEP patients had a comorbid SUD (Study 2). However, the biggest 
difference between IA and VA patients was found among FEP patients, with 
comorbidity being much more frequent among those who were IA (Study 2). When 
examining patients admitted to addiction treatment centers (Study 3), we found that 
comorbidities were common in both groups. Other studies of the prevalence of SUD 
in psychiatric clients have also shown variations from one sample to the next (10, 
64). The reason for this difference may be the methods used to assess SUD, the 
diagnostic criteria, the setting where the samples were obtained, and the 
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demographic characteristics of the samples. The particular demographics of the 
client population can also influence the estimated prevalence of SUD (12).  
Examining patients with comorbid SUD and mental health disorders, we found that 
the most frequent substance use diagnosis among patients admitted to acute 
psychiatric wards and addiction treatment centers was F19, multiple drug diagnosis 
(ICD-10). Using more than one substance predicts a higher level of mental distress 
(111). Alcohol, cannabis, and stimulants were the most commonly used substances 
in all three of our studies. Other studies have reported that the most used drugs 
among schizophrenic patients are alcohol, cannabis, and cocaine. The 
schizophrenia/cannabis comorbidity has even been characterized as an epidemic 
(12, 112-114). Studies of emergency unit departments have reported cannabis as the 
drug most often associated with exacerbated schizophrenia and acute psychotic 
episodes (115, 116). The use of substances with psychotomimetic properties, such 
as cocaine, amphetamines, hallucinogens, and cannabis, can provoke psychotic 
reactions that resemble primary psychotic disease (117).  
The findings in a review by Fiorentini et al. indicate that the propensity to develop 
psychosis seems to be a function of the severity of use and dependence (117). 
Distinguishing between primary and substance-induced psychoses is important. The 
symptoms of amphetamine-induced psychosis, as well as stimulant psychosis in 
general, will stop within 7–10 days of discontinuing the drug in nearly every case. 
However, some individuals with long-term or extensively use may continue 
experiencing intermittent psychotic episodes (e.g., hallucination, delusions, and/or 
paranoia) on an ongoing basis during the first year of abstinence (118).  
Most commonly, stimulant-induced psychosis occurs in drug users who take large 
doses of a stimulant and may reflect acting-out behavior (119-121). These patients 
  
57 
 
may be agitated, aggressive, hallucinating, demonstrate suicidal behavior, and 
require extensive resources when admitted to a hospital (122, 123). One query made 
among Norwegian psychologists found that, when the patients were violent, the 
psychologists would admit and treat the patients involuntarily (61). This finding 
confirms our findings in Study 1 that stimulant use is associated with involuntary 
admission.  
Several studies have shown that alcohol-dependent patients often have certain mood 
and anxiety disorders (124). The National Comorbidity Survey found that alcohol-
dependent patients are two to three times more likely than non-dependent patients to 
have an anxiety disorder (125). The National Longitudinal Alcohol Epidemiologic 
Survey (NIAAA) found that patients with a history of alcohol dependence (even 
former drinkers) have a more than four-fold increased risk of a major depressive 
episode compared to patients without a history of alcohol dependence (126). Alcohol 
seems to have a calming effect on anxiety in the short term, but a reinforcing effect in 
the long term (127). In Study 1, 26% of the IA patients and 40% of the VA patients 
were found to qualify for an alcohol diagnosis (F10) combined with mood disorders 
(F30). In Study 3, the mood disorder diagnoses were frequently found among both IA 
and VA patients. In addition, approximately one-third of IA and VA patients were 
diagnosed with a neurotic disorder (F40). In fact, neurotic disorder was the diagnostic 
group most frequently utilized in Study 3. In Study 1, 42% of the IA patients were 
diagnosed with schizophrenia disorders. Mueser et al. reported that 53% of all IA 
psychiatric patients (SUD and non-SUD patients) suffered from schizophrenia or 
schizoaffective disorders, and that alcohol was the most commonly abused 
substance (12).  
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However, other larger studies of the prevalence of specific types of substance abuse 
in clients with a variety of severe mental illnesses have failed to show whether 
patients diagnosed with certain psychiatric disorders are more prone to using 
particular types of substances (128, 129). The evidence suggests that the availability 
of different types of substances, rather than their subjective effects, is the primary 
determinant of which specific substance is used (130). 
In summary, we found that a large proportion of patients had comorbid psychiatric 
disorder and SUD characterized by the use of multiple drugs. The most frequent 
substance use diagnosis was F19, multiple drug diagnosis (ICD-10). Alcohol, 
cannabis, and stimulants were the most commonly used substances in all three of 
our studies. 
 
5.3 Aim 3 
In all our three studies, SUD had an influence on involuntary admission to hospitals. 
In Study 1, being IA to acute psychiatric wards was significantly associated with the 
use of stimulants (OR 2.3, 95% CI 1.266-4.099, P = 0.006). In addition to drug-
induced psychosis, stimulants also often resulted in an acting-out behavior; these 
patients may be agitated, aggressive, hallucinating, demonstrate suicidal behavior, 
and require extensive resources when admitted to the hospital (122, 123). The 
aggressive behavior, rather than the severity of the psychiatric disorder, may 
determine if admission to the hospital is voluntary or involuntary. Thus, one might 
question whether the Mental Health Care Act is used to protect society from non-
psychotic but aggressive patients intoxicated by stimulants. In fact, the findings in 
Study 3 indicate that the Social Services Act functions according to its purpose to 
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care for severely addicted patients with comorbid disorders who were in need of 
treatment. However, one can question whether the Social Service Act is applied 
according to its intention given the low number of patients IA pursuant to this law (see 
Fig. 2) compared to the much greater number of patients with comorbid SUD who 
were admitted pursuant to the Mental Health Care Act in Norway (Fig. 3).  
In Study 2, both SUD and non-SUD patients with FEP were included in the analysis. 
The presence of a SUD was significantly associated with involuntary hospitalization 
during follow-up (OR 5.2, 95% CI 1.654–16.498, P = 0.005). Power et al. found that 
most patients in the initial acute phase of FEP were admitted to hospital (131). Wade 
et al. concluded that SUDs are significantly associated with inpatient admission 
during follow-up; 76% of substance-abusing patients were hospitalized during the first 
3 months of treatment (132). In our study, 77 patients (75%) received voluntary 
treatment, and 26 patients (25%) received involuntary treatment at baseline. In a 
study by Opjordsmoen et al. that included inpatients only, 58% of the patients were 
treated voluntarily (133). If we exclude outpatients from our analysis, our findings 
were in accordance with their findings; 59% (61 patients) were voluntarily admitted. 
We also found that 60% (15 patients with SUD) had been IA during the first year, and 
the number increased to 18 patients (72%) in the second year. Involuntary admission 
to the hospital was approved for 26% of non-SUD patients during the first year; by 
year 2, 31% of non-SUD patients had undergone at least one involuntary admission. 
The difference between the involuntary admission rates of the two groups increased 
during the 2-year observation period. Thus, we found that comorbidity with SUD was 
significantly related to involuntary admission and readmission. 
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In Study 3, patients IA to addiction treatment centers pursuant to the Social Services 
Act were characterized by severe, long-term drug addiction. These patients were 
more often females, receiving public welfare benefits, and visiting physicians for 
somatic complaints. Other studies have also found that a pattern of severe substance 
use increases the risk of somatic disorders, including chronic disease, acute disease, 
and injuries (134, 135). Neither the severity of the mental illness nor the number of 
SUD diagnoses was associated with being IA. Kallert et al. and Priebe et al. found 
that patients have significant, but limited, improvements in their symptoms after 
involuntary treatment, possibly reflecting the severity of the underlying illness (136, 
137). Social factors, but not the psychiatric diagnosis, were important predictors of 
outcomes. 
The patients with SUD studied in these projects illuminate characteristics among a 
vulnerable group of patients that often exhibit comorbid SUD and mental health 
problems, but they may also exhibit somatic disorders. These patients are often sent 
back and forth between different treatment institutions (138). Landheim et al. found 
that 41% of patients in addiction treatment centers had been previously treated in 
mental health care (63). These patients had more severe mental disorders than 
patients who had only been treated in addiction treatment care. 
Both nationally and internationally, a divided support system for addiction treatment 
and mental health care is a major challenge for patients who have comorbid SUD 
and mental disorders. Despite the large differences in health care and social services 
between the U.S. and European countries, structural problems in interactions 
between addiction treatment services and mental health care sectors are a common 
feature (139). Landheim found that 70% of the patients in addiction treatment fulfill 
the requirements for mental health care (63). Thus, one could ask whether the 
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addiction treatment centers have the knowledge and skills needed to assess and 
treat these patients with severe mental disorders. Similarly, we can question whether 
mental health institutions have the required skills to adequately detect and treat SUD. 
Policymakers are faced with this ambivalence as they struggle with the extent to 
which SUD patients should be subjected to involuntary treatment (140).  
Similarly, patient reactions to experiences in compulsory care can be mixed. One 
Swedish study found that approximately half of patients report feelings of anger and 
violation, one-third are passive, and one-fifth are positive (50). In a study of 104 
patients with alcohol use disorders, 87% of the involuntarily treated and 52% of the 
voluntarily treated reported at the discharge interview that they felt that the coercive 
experiences were wrong or violated their personal integrity (141).  
In summary, in Studies 1 and 2 we found that SUD influenced involuntary admission 
to hospitals. Being IA to acute psychiatric wards was significantly associated with the 
use of stimulants. FEP patients with SUD also had a significantly higher risk of being 
IA to a hospital during the 2-year follow-up (OR 5.2). In Study 3, all patients were 
SUD patients and demographic characteristics, such as female gender, being on 
public welfare benefits, having more frequent visits to physicians for somatic 
complaints, injecting illicit drug abuse, and severe long-term drug addiction, were all 
associated with involuntary admission to addiction treatment centers pursuant to the 
Social Services Act.   
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6.0 Clinical implications 
 
Our findings do have some important implications for clinical practice. Simultaneous 
integrated treatment is recommended for both SUD and mental disease (12, 142). To 
provide adequate care, treatment centers caring for these and similar patients would 
likely benefit from expertise in both SUD and psychiatric disorders, as well as somatic 
disorders. These patients often have poor treatment outcomes, including problems 
with relapse, suicide, vulnerability to trauma, and re-hospitalization (144), and this 
must be taken into account when organizing treatment.  
Kessler et al. found that primary mental disorders strongly predict later SUD (145). 
Many patients with comorbid diagnoses report that mental disorders occurred at an 
early age, before their first SUD. This finding raises the question of whether early, 
successful treatment of primary mental disorders is effective in reducing subsequent 
SUDs. 
Finding conclusive evidence of how to use involuntary admission and treatment both 
for the benefit of the patient and to inform policy makers, health service providers, 
and the public is important (146). In psychological treatment, the therapeutic 
relationship is considered to be a necessary factor to achieve improvement (147, 
148).  
A good therapeutic relationship is usually based on the patient’s motivation and 
cooperation in treatment, and on voluntariness and mutual trust between the 
therapist and patient. However, mental health care with involuntary admission of 
patients who do not consent to treatment is not necessarily the premise of 
volunteerism and cooperation. Patients may have been persuaded, pressured, or 
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forced into treatment, and they often have very negative attitudes towards treatment. 
The degree of perceived coercion is likely to affect the interaction between patient 
and therapist. Focusing on the therapeutic relationship may reduce the patient's 
degree of perceived coercion and may contribute to increased satisfaction with 
inpatient mental health care, regardless of the legal status of the admission (48, 149).  
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7.0 Future research 
 
As indicated in this dissertation, a need exists for more research in the field; long-
term follow-up in particular is still lacking. Knowledge about SUD patients who are IA 
to a hospital is lacking for both the Mental Health Care Act and the Social Services 
Act. The research base needs to be broadened to better understand the mechanisms 
of comorbidity, which may enable us to more effectively prevent the occurrence of 
comorbidities and more effectively treat patients with comorbid disorders (150).  
First, a need exists to evaluate the impact of the use of involuntary admission and 
long-term treatment outcomes for this patient group. 
Second, an extensive need still exists for in-depth studies describing the patient’s 
experiences with the admission process and inpatient period. These patients 
experience many difficult situations that can be very stressful and humiliating. The 
degree of perceived coercion is likely to affect the interaction between patient and 
therapist. Focusing on the therapeutic relationship may reduce the patient's degree of 
perceived coercion and contribute to increased satisfaction with inpatient mental 
health care, regardless of the legal status of the admission. 
Thus, studying interventions that can increase respect for the patient’s needs and 
reduce the feeling of violation is important. Interventions should also include an 
assessment of the treatment alliance and, preferably, staff should be trained explicitly 
to both maintain and re-instate the alliance when a rupture is evident. Studying 
different ways to strengthen patient participation in the decision-making process 
during treatment is also important. 
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Practitioners have long expressed concern about the impact of a patient’s motivation 
on treatment outcomes. A lack of motivation is a common phenomenon in treatment, 
and the patient’s motivation is a critical factor determining treatment outcome. To 
determine if involuntary treatment is as useful as intended, investigating more about 
the patient group and treatment delivery is crucially important, as well as investigating 
whether the treatment manages to improve the motivation of IA patients. In addition 
to involuntary treatment, other formal and informal social pressures are placed on 
these patients that have to be considered. Informal coercion refers to the pressures 
the patients experience from sources other than the justice system, such as by an 
employer or family (151). Voluntarily treated individuals may also experience these 
types of pressures. Important control factors are the coercion perceived by the 
patient and the severity of problem, such as alcohol, drug, and psychiatric severity, 
which will influence motivation (152) and should be included in future studies.  
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8.0 Conclusion 
 
The main objective of this thesis was to explore the relationship between substance 
use patterns and involuntary admission to hospitals in different settings pursuant to 
the Mental Health Care and Social Services Acts. We found that a large proportion of 
the IA patients had comorbid SUD and psychiatric disorder. This comorbidity likely 
renders treatment more difficult. Patients diagnosed with comorbidities often require 
longer treatment duration and more carefully planned care to optimize treatment 
outcomes. This need presents a major challenge to the health service providers, 
indicating the need to diagnose and treat these patients within a highly competent 
system. Therefore, clinical routines that better identify and treat SUD among patients 
receiving mental health care should be given higher priority, as many of the patients 
would likely benefit from integrated specialist treatment. Study 3 also found that 60% 
of patients IA pursuant to the Social Services Act had mental disorders. These 
patients also required competent mental health treatment by a specialist. The study 
also found that the patients needed treatment for somatic health problems. 
Therefore, health providers must be educated to meet all of these different needs. 
Relatively little difference was found in the sociodemographic variables between 
patients IA pursuant to the Mental Health Care Act and those admitted pursuant to 
the Social Services Act. Given the relative low number of SUD patients IA to 
hospitals pursuant to the Social Services Act and the high proportion of SUD patients 
IA pursuant to the Mental Health Care Act, one can question if the laws are applied 
according to their intention and if patients with SUD are treated in the right system. 
Therefore, focusing on a more correct and consistent use of involuntary admissions 
and treatment within the right system is important.  
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ABSTRACT  
Background: Substance abuse and mental disorder comorbidity is high among patients admitted to acute psy-
chiatric wards. The aim of the study was to identify this co-occurrence as a reason for involuntary admission 
and if specific substance use-related diagnoses were associated with such admissions. 
Methods: The study was a part of a multicentre, cross-sectional national study carried out during 2005-2006 
within a research network of acute mental health services. Seventy-five percent of Norwegian hospitals provi-
ding acute in-patient treatment participated. Substance use was measured using the Clinician Rating Scale and 
the ICD-10 diagnoses F10-19. Diagnostic assessments were performed by the clinicians during hospital stay. 
Results: Overall, 33.2% (n=1,187) of the total patient population (3,506) were abusing alcohol or drugs prior to 
admission according to the Clinician Rating Scale. No difference in the overall prevalence of substance abuse-
related diagnoses between the two groups was found. Overall, 310 (26%) of the admissions, 216 voluntarily 
and 94 involuntarily admitted patients received a double diagnosis. Frequent comorbid combinations among 
voluntarily admitted patients were; a combination of alcohol and either mood disorder (40%) or multiple mental 
disorders (29%). Among involuntarily admitted patients, a combination of poly drug use and schizophrenia was 
most frequent (47%). Substance abusing patients diagnosed with mental and behavioral disorders due to the use 
of psychoactive stimulant substances had a significantly higher risk of involuntary hospitalization (OR 2.3). 
Conclusion: Nearly one third of substance abusing patients are involuntarily admitted to mental hospitals, in 
particular stimulant drug use was associated with involuntarily admissions. 
 
 
 
INTRODUCTION 
 
The prevalence of substance abuse (SA) among patients 
admitted to acute psychiatric wards varies according to 
setting and mode of measurement. Prevalence of such 
comorbidities among inpatients with severe mental ill-
ness ranges from 24.4% to 70.0% in reports from single 
wards [1-6]. Comorbid SA typically complicates re-
covery from mental health disorders and is associated 
with increased use of health services [7,8]. 
 Involuntary admission and treatment of mentally ill 
patients are controversial issues in mental health care 
worldwide [9]. The frequency of involuntary hospitali-
zations varies between and even within different coun-
tries, and is dependent on legislation, clinical experi-
ence, resources, traditions, and attitudes [4,5,10-13]. 
According to the Norwegian Mental Health Care Act 
[14], compulsory psychiatric mental health care may 
take place when the patient is suffering from a suspec-
ted or established serious mental disorder to prevent 
severe deterioration of the patient’s health status or in 
cases where there is an obvious threat to the patient’s 
own life or the life of others. 
 Involuntary admission rates to psychiatric hospitals 
in Norway are high compared to other European coun-
tries [12]. Published involuntary referral rates for 1998-
2000 from other Nordic and European countries range 
between 6 (in Portugal) and 218 (in Finland) per 
100,000 inhabitants/year [10,15,16]. In Norway, the 
respective incidence rates for civil commitment based 
on “involuntary referrals”, “treatment periods”, and 
number of persons involved were 259, 209, and 186 
per 100,000 adults/year according to a study conducted 
by Iversen et al. [12]. Based on the frequent application 
of coercive mental health care and the context of high 
rates of comorbid SA and mental illness in Norway 
[1,2,4], it is important to further investigate the role of 
substance abuse  among patients admitted to acute psy-
chiatric services. Previous studies have focused either 
on involuntary admissions and treatment in mental 
hospitals [4,5] or on substance abuse among mentally 
ill patients [1,2]. However, we have not been able to 
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find studies that have examined comorbidity and in-
voluntary admissions to hospitals. One of the aims of 
this study was to investigate if there were specific 
substance-related diagnoses associated with involun-
tary admissions. 
 In order to provide better treatment it is necessary to 
explore the extent to which the patient’s behavior, i.e. 
drug use prior to admission, predicts the application of 
coercion in psychiatric wards. 
 
Aims of the study  
1. To investigate if substance abusing patients had a 
higher risk of involuntary admission to acute psy-
chiatric wards. 
2. To investigate whether there could be typical 
patterns of diagnostic comorbidity of substance 
abuse and mental disorders among patients abusing 
psychoactive substances prior to admission to acute 
psychiatric wards. 
3. To investigate if there could be specific substance-
related diagnoses associated with involuntary 
admissions. 
 
 
MATERIALS AND METHODS 
 
Setting  
In Norway the application of coercive mental health 
care for the mentally ill patients is covered by the Men-
tal Health Care Act [14]. The most common causes for 
involuntary hospital admission in mental health care are 
schizophrenia, paranoid psychoses, and acute reactive 
psychoses [4]. Another act, the Social Services Act 
§6.2, covers an option for involuntary admission to the 
hospital for three months for persons without severe 
mental illness, but who are primarily addicted to psy-
choactive substances and whose substance abuse may 
cause risk to their physical or mental health [17]. In 
2009 in Norway, a total of 87 decisions were made for 
substance abusing persons for involuntary admissions 
to institutions according to the Social Services Act [18], 
whereas more than 7,200 patients were admitted invo-
luntarily based on the Psychiatric Healthcare Act [19]. 
Many of these were patients with substance abuse 
problems typically treated in psychiatric hospitals, 
rather than in drug treatment facilities [17]. 
 In 2004 the national health authorities reorganized 
the funding of alcohol and drug abuse treatment and 
the responsibility for provision of care was transferred 
from the counties to the Specialist Healthcare Authori-
ties. Currently, Social Services, together with the Psy-
chiatric Specialist Healthcare Services and the Specia-
list Substance Abuse Services, share joint responsible 
for SA patients. Nevertheless, these services often 
operate independently with limited interaction. Thus, 
the group of vulnerable substance abuse patients often 
experience problems when admitted to the Specialist 
Substance Abuse Services leaving them suffering from 
lack of treatment addressing their specific needs [18]. 
Study subjects  
This study was part of the cross-sectional Multicentre-
study of Acute Psychiatry (MAP) in Norway. The data 
collection was carried out as a national cross-sectional 
study during 2005 and 2006 within a research network 
of acute mental health services. Data on patient cha-
racteristics and treatment episodes were collected from 
all patients admitted during a three-month period. The 
network was organized and coordinated by the research 
institute SINTEF Health Research in Norway with 
support from the Norwegian Directorate of Health and 
Social Affairs [20,21]. 
 The sample originally consisted of 39 wards, which 
were categorized into three groups: 4 admission wards, 
28 acute wards, and 6 subacute wards. One ward was 
an intermediate term ward and was removed from the 
sample, resulting in a total of 38 acute wards. This com-
prised 75% of Norwegian hospitals providing acute in-
patient treatment. The clinics were located in both ur-
ban and rural parts of the country and were assumed to 
cover a representative sample of the Norwegian popu-
lation [20]. Data from 3,506 admissions to adult acute 
psychiatric wards were collected. Very few patients 
may have had more than one admission in the 3-month 
inclusion period. Thirty-five percent of patients were 
involuntarily admitted to the hospital [22]. 
 
Instrument and measures  
Drug and alcohol use during the six months prior to 
index hospital admission was assessed by the Clinician 
Rating Scale [23,24], which measures the consumption 
of psychoactive substances on a scale from 1 to 5. The 
ratings are 1 = no use, 2 = use without impairment, 3 = 
abuse, 4 = dependence, and 5 = dependence with need 
for institutionalization. The use of psychoactive sub-
stances without impairment is defined as “no evidence 
of persistent or recurrent problems in social functio-
ning, legal status, role functioning, mental status, or 
physical status, and no evidence of recurrent dange-
rous use”. The patients were subsequently divided into 
two groups:  
1. The non-substance abuse group including patients 
who scored 1 or 2 on the Clinician Rating Scale   
(for alcohol and/or drugs). 
2. The substance abuse group including patients who 
scored 3, 4, or 5 on the Clinician Rating Scale (for 
alcohol and/or drugs).  
Demographic, administrative, and clinical information, 
in addition to one primary and up to two secondary 
ICD-10 diagnoses [25], were recorded for each patient. 
Diagnoses were based on “routine clinical assess-
ments”, and on structured clinical interviews that mea-
sured SA over different time periods. The Clinician 
Rating Scale measured alcohol and drug use, respec-
tively, during the six months prior to admission, 
whereas ICD-10, F10-19 diagnoses represent current 
substance use disorders as judged by the clinician 
during the hospital stay. The focus of this study was on 
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Table 1.  Patient demographics and premorbid functioning of voluntarily and involuntarily hospi-
talized patients with substance abuse according to Clinician Rating Scale. 
 
  
Voluntary 
admission  
Involuntary 
admission   P-value 
N=1187 (%) 826 (70) 361 (30)  
Mean age (SD) 36.7 (12) 34.4 (11.9)   0.002 
Male (%) 63 64   0.705 
Living with partner (%) 18 15   0.140 
Housing    
  Rented or owned (%) 68 57 <0.001 
  Homeless or hospice (%) 11 11   0.931 
Employed (%) 10.2 8.6   0.459 
Education beyond primary school (%) 44 38   0.028 
Mean number of days since last discharge (SD) 110 (149) 91 (147)   0.105 
GAF symptoms at admission (mean/SD)* 39.2 (11.3) 30.7 (11.8) <0.000 
GAF social at admission (mean/SD)* 38.9 (9.8) 33.6 (10.5) <0.000 
Suicide risk at admission    
  Suicidal ideation or plans (%) 60.1 27.7 <0.000 
  No suicidal self-injurious behaviors (%) 9.0 5.5   0.058 
  Attempted suicide (%) 4.1 6.4   0.129 
  No suicide risk (%) 24.8 50.7 <0.000 
Suspect intoxicated on admission** (%) 48 57   0.006 
Positive alcohol test on admission (%) 13   9   0.059 
Positive drug test on admission (%) 12 20   0.001 
Police assisted admittance (%) 18 62 <0.001 
* Global Assessment of Social Functioning, scale from 0 to 100 with lower ratings for more severe problems 
** As judged by clinicians 
 
 
patients who reported drug use with impact/abuse pat-
tern before admission to acute psychiatric wards. We 
were therefore notably interested in patients scoring 3 
or higher on the Clinician Rating Scale; these patients 
formed the study sample and the basis for further ana-
lysis. Patients were tested for substance use by labora-
tory drug tests upon hospital admission. 
 The Global Assessment of Functioning Scale (GAF) 
was used to rate social, occupational, and psychologi-
cal functioning. The latter scores were split into symp-
tom scores (GAFs) and function scores (GAFf) [26]. 
No reliability tests were carried out. All clinicians had 
experience in rating GAF as a routine measure re-
quired in the mental health services. 
 
Analysis and statistical methods  
Continuous data are presented as means with standard 
deviations (SD) and analyzed using Student’s t-test 
when normal distributed. Multiple logistic regression 
analysis was performed to investigate whether specific 
substance-related diagnoses predicted involuntary 
admission (dependent variable). Results are presented 
with 95% confidence intervals. Continuous variables 
were checked for correlation with Spearman’s rho; 
none of the included continuous variables had a corre-
lation >0.7. Significance level was set at P <0.05. Ana-
lyses were performed using SPSS 16.0 software (SPSS 
Inc., Chicago, IL, USA). 
 
Ethics and informed consent  
The Regional Committee for Medical and Health Re-
search Ethics and the Data Inspectorate, Oslo, Norway 
(REK: 211-04049 NSD: 11074) approved the study. 
The Norwegian Directorate of Health and Social Affairs 
provided permission to collect information from health 
services. The Regional Committee for Medical and 
Health Research Ethics approved that data was collec-
ted without asking for consent, as it was considered 
ethically important also to include those that were 
involuntarily admitted and would be most likely to not 
give consent. 
 
 
RESULTS  
According to the Clinician Rating Scale, 1,187 of the 
3,506 admissions (33.2% of all admissions) were pati-
ents abusing psychoactive substances prior to admis-
sion. We found that 826 (70%) of the admissions were 
voluntarily admitted SA patients and 361 (30%) were 
involuntarily admitted SA patients (Table 1). 
 Two-thirds of both voluntarily and involuntarily ad-
mitted SA patients were males, mean age 36 years and 
34 years, respectively. Involuntarily admitted patients 
had more severe problems as measured by GAFs and 
GAFf scores. Significantly more voluntarily admitted 
patients than involuntarily admitted patients had suici-
dal ideation or plans (Table 1). Sixty-two percent of 
involuntary admissions and 18% of the voluntary ad-
missions required police assistance. Suspected intoxi-
cation rates at admission were higher among involun-
tarily admitted patients, in particular positive drug tests 
were found in up to one-fifth of those patients. 
 At discharge, 290 (35%) of the voluntarily and 131 
(36%) of the involuntarily admitted SA patients were
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Table 2.  Diagnosis according to ICD-10 of voluntarily and involuntarily hospitalized patients. 
 
  Total 
Voluntary 
admission (%) 
Involuntary 
admission (%) P-value 
Diagnosis (primary)     
  F 10-19 Substance use disorders  421 (35.5) 290 (35.1) 131 (36.3)   0.696 
  F 20-29 Schizophrenia disorders  201 (18.7)   88 (11.8) 113 (34.5) <0.001 
  F 30-39 Mood disorders  232 (21.6) 187 (25.1)   45 (13.7) <0.001 
  F 40-49 Neurotic disorder  94 (8.8)   84 (11.3) 10 (3.0) <0.001 
  F 60-69 Personality disorders 89 (8.3) 65 (8.7) 24 (7.3)   0.462 
Substance use diagnosis     
  (F10.) Alcohol 197 (16.6) 153 (18.5)   44 (12.2)   0,007 
  (F11.) Opioids 20 (1.7) 13 (1.6)   7 (1.9)   0.653 
  (F12.) Cannabinoids 22 (1.9) 14 (1.7)   8 (2.2)   0.540 
  (F13.) Sedatives or hypnotics 22 (1.9) 17 (2.1)   5 (1.4)   0.429 
  (F14.) Cocaine   1 (0.1)   1 (0.1) 0 (0)   0.508 
  (F15.) Other stimulants 49 (4.1) 24 (2.9) 25 (6.9)   0.001 
  (F16.) Hallucinogens 0 (0) 0 (0) 0 (0)  
  (F18.) Volatile solvents   1 (0.1)   1 (0.1) 0 (0)   0.508 
  (F19.) Poly drug 324 (27.3) 213 (25.8) 111 (30.7)   0.078 
  No substance diagnosis 551 (46.4) 390 (47.2) 161 (44.6)   0.442 
Total 1187 (100) 826 (100) 361 (100)  
 
 
 
Table 3.  Patterns of comorbid mental disorders and substance abuse disorders; ICD-10 diagnosis. 
 
 Admission 
F10 
Alcohol (%) 
F15 
Stimulant (%) 
F19 
Poly drug (%) Other* (%) Total (%) 
F20–F29 Schizophrenia disorders Voluntary  6 (8) 5 (39) 26 (28) 2 (6) 39 (18) 
 Involuntary    6 (22) 2 (40) 22 (47)   9 (60) 39 (42) 
F30-F39 Mood disorders Voluntary 30 (40) 2 (15) 23 (25) 15 (43) 70 (32) 
 Involuntary   7 (26) 1 (20) 4 (9)   4 (27) 17 (18) 
F40–F48 Neurotic disorders Voluntary  12 (16) 0 8 (9)   4 (11) 24 (11) 
 Involuntary  2 (7) 0 4 (9) 0 6 (6) 
F60–F69 Personality disorders Voluntary 1 (1) 2 (15) 16 (17)   6 (17) 25 (12) 
 Involuntary   3 (11) 1 (20) 10 (21) 1 (7) 16 (17) 
Multiple mental disorders Voluntary 22 (29) 2 (15) 13 (14)   8 (23) 45 (21) 
 Involuntary    8 (30) 1 (20)   6 (13) 1 (7) 16 (17) 
Other mental disorders Voluntary  4 (5) 2 (15) 7 (8) 0 13 (6) 
 Involuntary 1 (4) 0 1 (2) 0 2 (2) 
Total Voluntary    75 (100) 13 (100)   93 (100)   35 (100) 216 (100) 
 Involuntary    27 (100)   5 (100)   47 (100)   15 (100)   94 (100) 
* Use of one of: F11. opioids, F12. cannabinoids, F13. sedatives, F16. hallucinogens 
 
 
 
given a primary substance abuse diagnosis according 
to ICD-10 F10-F19 (Table 2). Of the primary mental 
diagnoses, mood disorders (F30-39) and neurotic dis-
orders (F40-49) were significantly more frequently 
diagnosed among patients admitted voluntarily. Schi-
zophrenia spectrum disorders (F20-29) were signifi-
cantly more common among the involuntarily admitted 
patients. Although no difference in the overall preva-
lence of substance abuse-related diagnoses between 
the two groups was found, there were differences in 
the specific patterns of drug abuse. Among voluntarily 
admitted patients, alcohol-related diagnoses were 
significantly more common, whereas stimulant drugs 
were significantly more common among involuntarily 
admitted patients. A tendency towards more polydrug 
use was observed in patients admitted involuntarily. 
 Overall, 310 of the SA admissions (216 voluntary 
and 94 involuntary admissions) received a double 
diagnosis (Table 3). Some typical comorbid patterns of 
drug use and mental disorders were found. Alcohol use 
or poly drug use were most frequent. Among the volun-
tarily admitted patients, a combination of alcohol and 
either mood disorder (40%), multiple mental disorders 
(29%), or neurotic disorder (16%) were more frequent. 
Among involuntarily admitted patients, a combination 
of poly drug use and schizophrenia was most frequent 
(47%). 
 Multiple logistic regression analysis was used to 
investigate whether being involuntarily hospitalized in 
acute psychiatric wards was associated with any spe-
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Table 4.  Drug diagnosis (ICD-10) patterns and associations with involuntary hospitalization in acute 
psychiatric wards. Bivariate and multivariate analyses. 
 
Characteristics 
Bivariate analysis 
unadjusted OR (95% CI) P-value  
Multivariate analysis 
adjusted OR (95% CI) P-value 
Male gender 0.943 (0.729-1.221) 0.657  0.939 (0.722-1.223) 0.642 
Age 0.984 (0.973-0.994) 0.002  0.989 (0.977-1.000) 0.046 
Substance use Diagnosis       
  No abuse diagnosis reference     
  Alcohol 0.700 (0.478-1.026) 0.068  0.751 (0.507-1.111) 0.152 
  Stimulant 2.536 (1.407-4.573) 0.002  2.278 (1.266-4.099) 0.006 
  Multiple drugs 1.269 (0.946-1.702) 0.112  1.181 (0.873-1.598) 0.281 
  Other 1.107 (0.632-1.937) 0.722  1.062 (0.607-1.859) 0.833 
 
 
 
cific drug use patterns. The use of stimulants was sig-
nificantly associated with involuntary admission (OR 
2.3, 95% CI 1.266-4.099, P=0.006) (Table 4). 
 
 
DISCUSSION 
 
One-third (33.2%) of the total hospital admissions 
(n=3,506) were patients abusing psychoactive substan-
ces prior to admission to acute psychiatric wards 
according to the Clinician Rating Scale. Of these, 70% 
were voluntarily admitted and 30% involuntarily ad-
mitted. No difference in the overall prevalence of 
substance abuse-related diagnoses between the two 
groups was found. Among voluntarily admitted SA 
patients, alcohol-related diagnoses were significantly 
more common. A tendency towards more polydrug use 
was observed in patients admitted involuntarily. SA 
patients diagnosed with mental disorders due to stimu-
lant use had a significantly higher risk for involuntary 
hospitalization (OR 2.3). 
 
Prevalence and characteristics  
Using the Clinician Rating Scale revealed a prevalence 
of substance abuse among patients admitted to acute 
psychiatric wards of 33.2%, which is concordant with 
similar previous studies. In these studies using the 
same Clinical Rating Scale as a screening tool on 
smaller and more selected populations, the reported 
prevalence varies between 24% and 69% [8,27-29]. 
Studies reporting prevalence of substance use based on 
self-report tended to underestimate the prevalence 
compared with studies based on laboratory or on-site 
drug analyses [30]. 
 Involuntarily admitted patients tested positive signi-
ficantly more often for substances on drug tests per-
formed at hospital admission. They were more often 
suspected to be intoxicated. Police assisted admissions 
were more frequently required (Table 1). However, it 
is noteworthy that as many as 18% of the voluntary ad-
missions also required police assistance. Several studies 
suggest that the patients’ experience of being coerced 
during the admission process to mental hospitals do 
not necessarily correspond with their legal status [31, 
32]. Rather, perceived coercion appears to be associated 
with a feeling that their views were not taken into 
consideration in the admission process. In a study by 
Iversen et al. 32% of voluntarily admitted patients 
perceived high levels of coercion in respective of legal 
status at admission. 
 
Diagnoses and diagnostic comorbidity  
Different modes of substance use detection often result 
in different prevalence estimates. Applying the Clinici-
ans Rating Scale revealed more substance abusers than 
that diagnosed by clinicians according to ICD-10 co-
ding. According to the Clinicians Rating Scale, 1,187 
of the admissions were patients abusing psychoactive 
substances. However, only 53% of these received a 
substance abuse diagnosis according to ICD-10.  
 Some typical patterns of diagnostic comorbidity of 
SA and mental disorders among patients abusing psy-
choactive substances prior to admission were found. 
Alcohol and polydrug use were the two most frequent-
ly observed patterns. Among patients admitted volun-
tarily, a combination of alcohol and either mood disor-
ders, multiple mental disorders, or neurotic disorders 
were common, whereas a combination of polydrug use 
and schizophrenia was most frequent among involun-
tarily admitted patients. This is in agreement with the 
study of Mueser et al. who reported that 53% of all the 
involuntarily hospitalized psychiatric patients (SA and 
non-SA patients) suffered from schizophrenia or 
schizoaffective disorders, and alcohol was the most 
commonly abused substance [24]. 
 SA patients diagnosed with mental and behavioral 
disorders due to psychoactive stimulant use had a sig-
nificant higher risk for involuntary hospitalization (OR 
2.3). This could be due to stimulant-induced psychosis 
or it may reflect acting-out behavior among stimulant-
using patients. Most commonly, stimulant psychosis 
occurs in drug abusers who take large stimulant doses 
[33-35]. In nearly every case, the symptoms of 
amphetamine-induced psychosis (as well as stimulant 
psychosis in general) will stop within 7–10 days of 
discontinuing the drug. However, some individuals with 
long-term or "heavy" use may continue experiencing 
intermittent psychotic episodes (hallucination, delu-
sions, and/or paranoia) on an ongoing basis during the 
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first year of abstinence [36]. It is clinically challenging 
to differentiate between a drug-induced psychosis and 
other forms of psychosis during the initial phase. 
 Stimulants seem to predict involuntary admission in 
our study. Besides stimulant-induced psychosis, stimu-
lants also often produce an acting-out behaviour and 
these patients may be agitated, aggressive, hallucina-
ting, demonstrate suicidal behaviour, and require ex-
tensive resources when admitted to the hospital [37, 
38]. The aggressive behavior rather than the degree of 
severity of the psychiatric disorder could determinate 
if admission to hospital becomes voluntary or involun-
tary. It is of concern if the Mental Health Act designed 
to provide health care for psychotic patients is regular-
ly used towards non-psychotic but aggressive patients 
intoxicated by stimulant drugs. 
 There are some methodological considerations to 
recognize when interpreting results from this study. 
First, the cross-sectional study design can only provide 
associations, not causation. Second, the diagnoses used 
in this study are clinical diagnoses and not necessarily 
based on any standardized, structured interviews. Ne-
vertheless, this study has a relatively large sample size, 
is nationally representative, and may have the power to 
detect important associations of clinical significance. 
The large data collection represents the diagnostic reali-
ty in a large number of clinical settings in Norway, and 
not only in a strictly controlled experiment. 
 This study indicates that more than half (53%) of 
patients abusing substances prior to admission to acute 
psychiatric wards, addiction treatment alone or in com-
bination with treatment for mental disorders may be 
more appropriate than mental disorder treatment alone. 
This and other studies have shown that SA and mental 
disorders are co-occurring and comorbidity renders 
treatment more difficult, leading to greater use of 
health services [8,39]. Therefore, clinical routines to 
better identify SA among patients receiving mental 
healthcare should be given higher priority in order to 
provide optimal treatment, as many of the patients like-
ly would benefit from additional treatment in specialist 
substance abuse services. 
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Abstract 
 
Background: To investigate factors associated with involuntary admissions to hospital 
pursuant to the Social Services Act of patients with substance use disorder by comparing the 
socio-demographic characteristics, substance use, and psychiatric comorbidities with 
voluntarily admitted patients.    
Methods: This cross-sectional study compared two groups admitted to combined substance 
use disorder and psychiatry wards. Sixty-five patients were involuntarily admitted pursuant to 
the Social Services Act and 137 were voluntarily admitted. The International Classification of 
Diseases and Related Health Problems was used for diagnostic purposes regarding substance 
use disorders, type and severity of psychiatric problems, and level of functioning. Socio-
demographic variables were measured using the European Addiction Severity Index, and the 
Symptom Checklist-90-R instruments were used to evaluate the range of psychological 
problems and psychopathological symptoms. Logistic regression was performed to investigate 
the relationship between involuntary admissions and patients characteristics. 
Results: Patients who had been involuntarily admitted were more often females, had utilized 
public welfare services more often, more severe substance use patterns, and more frequent 
visits to physicians for somatic complaints in the past 6 months, but had fewer comorbid 
mental disorders. Still, considerable burdens of comorbid substance use disorders and mental 
disorders were observed both among involuntary and voluntary admitted patients. 
Conclusions: To meet the needs of these patients with complex and mixed disorders, 
treatment centers should offer diagnostic skills and therapy regarding substance use disorders, 
psychiatric disorders, and somatic disorders. 
Keywords: Substance use disorder; comorbidity; involuntary admission, mental disorders 
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Introduction 
Substance dependence is a chronic relapsing disease that typically leads to psychiatric, 
somatic, and social comorbidities, often with shortened life expectancy [1]. In contrast to 
other patients with chronic diseases, patients with substance use disorders (SUDs) sometimes 
refuse treatment owing to denial of their own disorder, feelings of hopelessness, or a negative 
attitude toward treatment [2, 3]. In many countries, the involuntary admission of SUD patients 
to institutions has been a controversial option when voluntary care has proven unsuccessful 
[4]. As of 2001, 73 of 90 countries worldwide provided some form of compulsory 
commitment (acute or rehabilitative) motivated by the intent to protect an otherwise legally 
capable individual who is in a self-destructive and vulnerable situation because of substance 
use [5]. In the literature, three main legislative domains have been described as foundations 
for the mandated treatment of SUD patients: mental health care acts or social services acts (in 
combination called civil commitment), and criminal justice acts. Although most countries 
may apply one or more of these acts to SUD patients, not all countries provide all three 
alternatives [4]. Literature from the United States has been dominated by drug courts’ studies 
of treatment as an alternative to prison [6]. Psychiatric research often reports on involuntary 
versus voluntary treatment. Less focus has been paid to SUD patients in treatment pursuant to 
the mental health care acts, although a considerable proportion of these patients are SUD 
patients [7, 8]. 
 
The Norwegian Mental Health Care Act (§§ 3.2 and 3.3) is designed for patients based on 
their need for psychiatric care. Involuntary commitment is an option only for persons who are 
found by a medical professional or psychologist to be incapable of assessing their own need 
for care. Such incapacity is only stated when patients are severely mentally ill (psychotic) and 
may be a danger to themselves or others [9]. In 2010, there were approximately 8300 
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involuntary admissions to mental health care units in Norwegian hospitals pursuant to this law 
[10]. Approximately one-third of patients involuntarily admitted to mental health care 
hospitals had a substance use disorder [11]. 
 
The Norwegian Social Services Act (§ 6.2) warrants involuntary interventions for non-
psychotic adult patients with SUDs. The act covers an option for retention (up to three 
months) when the health of the patient is seriously at risk because of extensive and prolonged 
substance use, and voluntary efforts have shown to be insufficient. In Norway, voluntary and 
involuntarily admitted SUD patients are often treated within the same wards, and using the 
same kind of therapy. In the acute phase, the main target of retention is to provide life-saving 
treatment; in the longer term, the aim is to motivate patients to enter voluntary treatment [12]. 
During 2010, only 106 decisions were made for the involuntary admission of SUD patients to 
institutions pursuant to the Social Services Act [13]. 
Involuntary commitment of non-psychotic SUD patients, although a relatively marginal 
phenomenon, is controversial. Such interference with personal autonomy should not be 
applied without an evidence-based foundation [14]. In Sweden, the phenomenon of SUD 
patients in compulsory care pursuant to social services acts has to some extend been explored 
[15]. However the acts in these two countries differ considerably and Swedish results may not 
be directly applicable to Norwegian settings. Thus far, little is known regarding the 
characteristics of involuntarily admitted patients in Norway and the factors associated with 
these admissions. This study addresses this knowledge gap and focuses on SUD patients who 
have been involuntarily admitted to institutions pursuant to the Social Services Act §6.2. 
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Aims of the study 
The aims of the study were to describe the socio-demographic characteristics, substance use 
patterns, and psychiatric comorbidities among SUD-patients involuntary admitted to hospital 
pursuant to the Social Services Act by comparing them with voluntarily admitted patients. In 
addition factors associated with involuntarily admission to treatment institutions were 
investigated. 
 
Materials and methods 
Study subjects 
This cross-sectional study compared two groups: involuntarily and voluntarily admitted 
patients admitted to combined substance use disorder and psychiatry wards. Involuntarily 
admitted (IA) patients were included from three different publicly funded treatment centers in 
the southeastern part of Norway. The centers were located in Kristiansand, Tønsberg, and 
Oslo, and had 4, 4, and 3 beds for IA patients, respectively. All of the voluntarily admitted 
(VA) patients were from the same ward of the Kristiansand center as the IA patients. All 
wards were multidisciplinary (psychiatrists, psychologists, social workers, occupational 
therapists, specialized nurses, and other trained staff) and had specialized units that offered 
treatment for patients with primary SUD often combined with mental disorders (except 
psychosis). Treatment included assessments of somatic and mental health, with diagnoses 
based on a structured interview and examination in accordance with the International 
Classification of Diseases and Related Health Problems, 10th Revision (ICD-10); 
pharmacotherapy; cognitive milieu therapy; and individual motivation enhancement. The 
patient population was recruited mainly from urban and suburban areas. 
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Recruitment for the study continued consecutively from January 1, 2009 to May 31, 2011. 
The criteria for inclusion were as follows: substance abuse or dependence, age > 18 years, 
understanding/speaking the Norwegian language, and at least 3 weeks of treatment (so that 
abstinent patients could be interviewed). 
Before inclusion, both the IA group and the VA group of patients were detoxified, verified by 
either negative urine tests of alcohol, opioids, central stimulants (amphetamines, 
methamphetamines, and cocaine), benzodiazepines, and cannabis, or a minimum of 14 days 
spent in detoxification. Patients with mental retardation (IQ < 70) who were not able to 
understand the questionnaires were excluded. Because pregnant SUD patients are treated in 
special wards, they were not included in this study. 
Altogether, 103 consecutive IA patients were identified. Fifteen did not meet the inclusion 
criteria (12 because their stay was too short, and 3 because of insufficient mental capacity), 
11 were not asked to participate owing to logistical issues. Of the 77 patients eligible for 
inclucion12 refused to participate. Therefore, the rate of consent to participate was 84% (65 
patients). There were 223 VA patients identified; 72 patients were excluded (69 because their 
stay was too short, 3 because of insufficient mental capacity). Of the remaining 151VA 
patients, 14 refused to participate. Therefore, rate of consent in the VA group was 91% (137 
patients). 
The study was approved by The National Committee for Research Ethics in Norway (REK 
08/206d, 2008/2900, 09/2413) and by the Privacy Issues Unit, Norwegian Social Science Data 
Services (NSD no. 18782). Written informed consent was obtained from all study 
participants.  
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Instruments and measures 
The ICD-10 was used for diagnostic purposes regarding current substance abuse, current type 
and severity of psychiatric problems, and level of functioning [16]. All patients were 
subjected to a clinical psychiatric examination supported by the Mini-International 
Neuropsychiatric Interview (MINI) version 2005. The MINI is a short psychiatric interview 
for the assessment of psychiatric disorders in accordance with the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) and ICD-10 classification systems 
[17], and has high acceptance and validity [18, 19]. The interviews were conducted by senior 
psychiatrists and psychologists who had many years of clinical and research experience with 
the psychiatric assessment of patients with physical disorders. In the statistical analysis, 
psychiatric diagnoses were categorized as serious mental illness (F 20-39, which includes 
schizophrenia and mood disorders) or other mental illnesses (F 40-99) [20]. Injecting illicit 
drugs during the past 6 months before admission and lifetime prevalence of overdoses were 
used as indicators for severe substance abuse. 
Socio-demographic variables were measured using the European Addiction Severity Index 
(EuropASI); a personal, structured interview designed for both clinical and research purposes. 
It includes 7 areas: medical status, employment and support status, drug and alcohol use, legal 
status, family history, family and social relationships, and psychiatric status [21]. The 
EuropASI interviews were performed by trained and certified staff. Specific substance use 
patterns based on the EuropASI were dichotomized into drug consumption at least once 
weekly versus less than weekly. The Symptom Checklist-90-R (SCL-90-R) instrument was 
used to evaluate the range of psychological problems and symptoms of psychopathology. The 
SCL-90-R test contains 90 items, measures 9 primary symptom dimensions, and provides an 
overview of a patient's symptoms and their intensity. Each of the 90 items is rated on a five-
point Likert-type scale, ranging from “not at all” (0) to “extremely” (4): higher values indicate 
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greater symptom severity during the past week. The Global Symptom Index (GSI) score was 
used to assess the level of general psychological distress [22]. 
 
Analysis and statistical methods 
Continuous variables are reported with means and standard deviations. Categorical variables 
are reported as frequencies. The independent sample t-test, Chi-squared test, and Fisher’s 
exact test were used to test for statistically significant differences between groups. Logistic 
regression was performed to investigate the relationship between involuntary admissions and 
patient characteristics. Results are presented with 95% confidence intervals. Continuous 
variables were checked for correlation with Spearman’s rho. None of the included continuous 
variables had a correlation exceeding 0.7. The number of cases in the sample restricted the 
predictors included in the model. From univariate analysis, variables with a P-value < 0.10 
were included in the multivariate analyses except “overdoses on drugs” because of 
multicollinearity with the variable “injecting illicit drugs”. The threshold for statistical 
significance was P < 0.05. Analyses were performed using SPSS 18.0 Software (SPSS Inc., 
Chicago, IL, USA). 
 
Results 
Patient characteristics 
We found several differences between the IA and the VA groups (Table 1). There were 
significantly more female patients among the IA patients compared with the VA patients 
(48% vs. 27%; P = 0.004). During the 6 months prior to admission, significantly more IA 
patients received financial support from public welfare benefits, and were more often 
injecting illicit drugs. In addition, IA patients had experienced more overdoses during their 
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lifetime compare with VA patients. IA patients had also significantly more frequent visits to 
physicians for somatic complaints during the 6 months prior to admission. However, the 
burden of psychological symptoms (SCL-90-R and suicide attempts) was higher in the VA 
group. 
 
Mental health diagnoses and substance use disorders 
All patients met the ICD-10 criteria for current substance dependence or abuse. IA patients 
were using alcohol, benzodiazepines and other sedatives, and heroin significantly more often 
than VA patients (Table 2). Significantly more IA patients received “no mental diagnoses”, 
but among those with comorbid mental disorders, no significant differences were observed 
between the two groups regarding mental health diagnosis. The most common mental 
diagnoses among both IA and VA patients were F40-49 neurotic disorders, F 90 attention-
deficit hyperactivity disorder (AD/HD), and F30-39 mood disorders. Among the personality 
disorders (F 60), emotionally unstable personality disorder (F 60.3) was the most common in 
both groups (8% of IA patients and 7% of VA patients) (Table 3). 
Multiple logistic regression analysis was used to investigate whether being involuntarily 
admitted to an institution was associated with any specific patterns. Female gender, receiving 
public welfare benefits, and more frequent visits to physicians  for somatic complains   or 
injection of drugs during 6 months prior to treatment were all associated with involuntarily 
admission pursuant to the Social Services Act (Table 4). Neither the severity of the mental 
illness nor the number of substance use diagnoses were associated with being involuntarily 
admitted. 
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Discussion 
Overall, SUD patients in the IA group were characterized by severe drug dependence (defined 
as injection of drugs and high prevalence of overdoses), often combined with the need for 
public welfare benefits and a history of more frequent visits to physicians for somatic 
complaints.   Comorbid substance use disorders and mental disorders were observed among 
the majority of patients in both groups, although the burden of psychological symptoms 
(SCL-90-R and suicide attempts) was somewhat higher in the VA group.   
 
Characteristics of involuntarily admitted patients 
The substance users included in this study were relatively young, with a mean age of 29 years 
for IA patients. This is somewhat younger than what was reported by a national study of 
substance abusers involuntarily admitted to acute psychiatric wards pursuant to the Mental 
Health Care Act (mean age, 34 years) [11]. 
In Norway, approximately 70% of persons with SUDs are men [23]. In accordance with this 
statistic, we observed that, overall, 66% of patients were men. Although the majority of 
substance users were male, we observed nearly twice as many females among the IA patients 
compared with the VA patients. Social workers have reported that the reason for the relative 
excess of female patients in involuntary treatment might be that the service providers 
considered women more vulnerable and exposed to violence and prostitution [24]. The 
opposite sex distribution was reported by the Swedish National Board of Institutional Care: 
only one-third of the substance users in compulsory care pursuant to the social services act 
were women [25]. Psychiatric hospitals in Norway are characterized by the typical sex 
distribution, with more women than men among inpatients; however, men are more often 
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involuntarily admitted [8, 26]. Overall, 64% of substance users involuntarily admitted to acute 
psychiatric wards pursuant to the Mental Health Care Act were male [27]. 
 
Severity of drug dependence 
IA patients exhibited more severe drug use patterns than VA patients. Significantly more IA 
than VA patients had been injecting illicit drugs during the last 6 months before admission 
(71% vs. 46%). Injection of drugs implies both the strongest involvement with drug use and 
the highest risk of substance-related morbidity and mortality. Among IA patients, 70% also 
reported a history of lifetime overdose experiences. According to an overview by Bohnert et 
al., the lifetime prevalence of overdoses among drug users ranges between 43% and 74% [28]. 
Hence, the studied population of SUD patients appears to exhibit a particularly high-risk drug 
use profile. 
Polydrug diagnoses tend to be more common among IA patients (P= 0.05). According to the 
EuropASI interviews, IA patients exhibited a consistently higher prevalence of drug use: 
alcohol, benzodiazepines, other sedatives, and heroin were consumed significantly more 
often. These findings are similar to those reported in Swedish studies which observed that IA 
patients were more often drug users and polydrug users, while VA patients more often abused 
alcohol [15].The high prevalence of polydrug use is a current trend reported in other studies 
of psychiatric disorders among SUD patients [11, 15]. 
 
Mental diagnoses and comorbidity 
Psychiatric comorbidity has previously been identified among patients admitted involuntarily 
pursuant to the Mental Health Care Act [10, 11, 26], including the patients admitted pursuant 
to the Social Services Act in this study. Although there were no significant differences 
between the types of mental diagnoses, significantly more IA patients had no mental 
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diagnoses (40% vs. 26%). In an overview of several studies from Sweden, it was observed 
that 50% to 60% of patients seeking help for substance use disorders did have another 
psychiatric disorder [15]. Other studies have found that among patients seeking help for 
psychiatric disorders, between 24% and 70% also had a substance abuse problem [29-33]. It 
has also been shown that comorbidity contributes to re-admission for substance use disorder 
patients, as well as for those with mental disorders [26, 34]. 
IA patients had also significantly more frequent visits to physicians for somatic complaints 
during the past 6 months (42% of IA patients, compared with 25% of VA patients). This 
finding indicates that a pattern of severe substance use also increases the risk of somatic 
disorders.  High prevalence of chronic disease, acute disease, and injuries among SUD 
patients have also been demonstrated by others [35, 36]. The SUD patients studied in this 
project illuminate characteristics among a vulnerable group of patients that often exhibit 
combined SUD and mental health problems, but also exhibit somatic disorders in addition. 
Therefore, comorbidities appear to be particularly relevant. To provide adequate care, 
treatment centers caring for the needs of these and similar patients would likely benefit from 
expertise in substance use disorders, psychiatric disorders, and somatic disorders. 
There are some methodological considerations to recognize when interpreting these results. 
First, the comparison of the two groups, IA patients and VA patients, may be somewhat 
problematic: VA patients may generally be expected to be more motivated for treatment and 
more cooperative than IA patients. However, the groups’ characteristics regarding age, 
education, living conditions, and mental health status were similar. The VA patients had all 
been considered to qualify for treatment in a hospital. Second, to establish accurate diagnosis 
for patients with concurrent substance abuse, mental, and somatic disorders can be a 
challenge. There will always be a risk of misdiagnosing, underreporting, or overreporting 
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illnesses. Furthermore, it is difficult to make comparisons between studies and countries 
owing to differences in laws and diagnostic procedures [37]. 
This study addresses the knowledge gap and focuses on SUD patients who have been 
involuntarily admitted to institutions pursuant to the Social Services Act §6.2. Our findings of 
which factors that are associated with involuntary admissions to hospital of these patients 
may provide useful knowledge that clinical practitioners and authorities would benefit from.  
We found that, rather than ICD-10 diagnoses, demographic characteristics and severity of 
drug use (injecting drugs, overdoses) were associated with involuntary admission to a 
treatment institution in this study. Female gender, receiving public welfare benefits, frequent 
visits to physicians for somatic complaints, and drug injection during the past 6 months were 
all associated with involuntarily admission pursuant to the Social Services Act.  
In sum, the factors associated with involuntary admission presented in this study indicate that 
“poverty”, somatic complaints, and a perception of females who use injection substances as 
“victims of addiction” characterize patients involuntarily admitted to treatment for substance 
use disorders in Norway. Patients diagnosed with comorbidity will often require a longer time 
in treatment and more carefully planned care to optimize treatment outcomes. The 
concurrence of SUD, mental, and somatic complaints presents a major challenge to health 
service providers, indicating the need to diagnose and treat these patients within a highly 
competent system. 
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Table 1.         
Baseline socio-demographic variables and mental stress scores for substance abuse patients voluntarily or 
involuntarily admitted to addiction treatment centers 
  
Involuntary 
n/ 
Voluntary 
n 
  Involuntary    Voluntary   P-value 
Age, mean (SD) 65/137  29 (10.6)  31 (8.9)  0.229 
Female (%) 65/137  31 (47.7)  37 (27)  0.004 
Education        
Mean years in primary and high school (SD) 59/130  10.53 (1.4)  10.59 (1.6)  0.783 
Mean years in college/university (SD) 59/130  0.17 (0.8)  0.31 (1.0)  0.352 
Sources of financial supporta, c        
Employment (%) 60/130  6 (10.0)  24 (18.5)  0.137 
Unemployment compensation (%) 60/130  2 (3.3)  4 (3.1)  1.000 
Public welfare benefits (%)   62/135  59 (95.2)  115 (85.2)  0.043 
Mate, family, or friends (%) 60/130  17 (28.3)  37 (28.5)  0.985 
Illegal activity (%) 60/130  24 (40.0)  47 (36.2)  0.610 
Prostitution (%) 60/130  3 (5.0)  1 (0.8)  0.094 
Usual living arrangementc         
With partner (%) 60/130  8 (13.3)  11 (8.5)  0.298 
Alone (%) 60/130  31 (51.7)  62 (47.7)  0.610 
With family (%) 60/130  9 (15.0)  26 (20.0)  0.409 
No stable arrangement (%) 60/130  9 (15.0)  16 (12.3)  0.610 
Controlled environment (%) 60/130 2 (3.3)  15 (11.5)  0.065 
Visits to physician for somatic complaintsc (%) 60/130  24 (40.0)  32 (24.6)  0.031 
Injecting illicit drugc (%) 61/134  43 (70.5)  62 (46.3)  0.002 
Alcohol delirium tremensd (%) 59/130  9 (15.3)  15 (11.5)  0.477 
Drug overdosesd (%) 59/130  41 (69.5)  63 (48.5)  0.007 
Suicide attemptsd (%) 60/131  23 (38.3)  71 (54.2)  0.042 
Mental stress score        
SCL-90-R GSIᵇ, mean (SD) 62/135   1.04 (0.7)   1.28 (0.7)   0.023 
ᵃSome have more than one source of financial support        
ᵇSCL-90-R GSI, Symptom Check List-90-revised, Global Symptom Index    
cLast 6 months before admission, dLifetime prevalence    
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Table 2.        
Substance abuse with respect to ICD-10 diagnosis and Addiction Severity Index of patients 
voluntarily and involuntarily admitted to addiction treatment centers 
  
Involuntary 
n/ 
Voluntary 
n   
Involuntary 
(%) 
  
Voluntary 
(%) 
  
P-value 
F10-19 Substance abuse disorders         
Single substance  65/137  9 (13.8)  32 (23.4)  0.116 
Two substances  65/137  11 (16.9)  30 (21.9)  0.412 
Three or more substances  65/137  45 (69.2)  75 (54.7)  0.050 
Substance Abuseᵃᵇ        
Alcohol 60/132 29 (48.3)  41 (31.1) 0.021 
Heroin 61/134 21 (34.4)  18 (13.4) 0.001 
Other opiates 60/130 11 (18.3)  25 (19.2) 0.883 
Benzodiazepines, other sedatives 60/134 39 (65.0)  63 (47.0) 0.020 
Amphetamines 62/135 35 (56.5)  67 (49.6) 0.374 
Cannabis 61/133 32 (52.5)  71 (53.4) 0.905 
Cocaine, inhalants, hallucinogens 60/132 12 (20.0)  18 (13.6) 0.260 
ᵃSome patients abuse more than one substance, ᵇLast 6 months before admission 
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Table 3.       
Current ICD-10 diagnoses of patients voluntarily and involuntarily admitted to addiction treatment 
centers 
Diagnosis  
  
Involuntary 
(%)   
Voluntary 
(%)   
P-value 
Mental diagnosis       
No mental diagnosis  26 (40.0)  35 (25.5)  0.037 
Severe mental diagnoses (F20-F39)  14 (21.5)  38 (27.7)  0.347 
Other mental diagnoses (F40-F99)  25 (38.5)  64 (46.7)  0.270 
F 20-90 Mental disordersᵃ       
(F 20.) Schizophrenia disorders   5 (7.7)  5 (3.6)  0.297 
(F 30.) Mood disorders   9 (13.8)  33 (24.1)  0.094 
(F 40.) Neurotic disorders  18 (27.7)  48 (35.0)  0.298 
(F 50.) Behavioral syndromes   1 (1.5)  4 (2.9)  1.000 
(F 60.) Personality disorders  8 (12.3)  22 (16.1)  0.484 
(F 70.) Mental retardation  1 (1.5)  0   
(F 80.) Developmental disorders  1 (1.5)  0   
(F 90.) Attention-deficit hyperactivity disorders  11 (16.9)  35 (25.5)  0.172 
N=   65   137     
ᵃSome patients have more than one mental diagnosis 
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Table 4.         
Logistic regression analysis of the effect of involuntary admission to addiction treatment centers pursuant to the 
Norwegian Social Services Act on independent variables 
Characteristics   Bivariate analysis ORᵃ (95% CI)   
P-
value   
Multivariate analysis 
ORᵇ (95% CI)    
P-
value 
Sex (female)  2.464 (1.331-4.561)  0.004  2.424 (1.174-5.003)  0.017 
Public welfare benefits  3.420 (0.977-11.979)  0.054  4.029 (1.022-15.877)  0.046 
Visits to physician for somatic complaintsc  2.042 (1.063-3.921)  0.032  2.208 (1.032-4.725)  0.041 
Substance abuse diagnosis         
Single substance   reference    reference   
Two substances   1.304 (0.474-3.587)  0.608  0.626 (0.184-2.129)  0.454 
Three or more substances   2.133 (0.933-4.876)  0.072  1.034 (0.381-2.809)  0.947 
Injection drug abuse in the last 6 months  2.774 (1.453-5.296)  0.002  2.925 (1.338-6.392)  0.007 
Mental diagnosis         
No mental diagnosis  reference    reference   
Severe mental diagnoses (F20-F39)  0.496 (0.224-1.099)  0.084  0.532 (0.196-1.443)  0.215 
Other mental diagnoses (F40-F99)  0.526 (0.265-1.045)  0.066  0.679 (0.293-1.547)  0.367 
Suicide attempts (lifetime)  0.525 (0.282-0.980)  0.043  0.519 (0.244-1.105)  0.089 
Scl-90-R GSI   0.581 (0.363-0.929)   0.023   0.693 (0.401-1.199)   0.190 
ᵃunadjusted OR, ᵇadjusted OR, ᶜLast 6 months before admission       
 

